Neuroimmune mechanisms in chronic inflammation : translational studies of the inflammatory reflex by Estelius, Johanna
From the Department of Medicine, Solna 
  
NEUROIMMUNE MECHANISMS IN 
CHRONIC INFLAMMATION  
– TRANSLATIONAL STUDIES OF THE 
INFLAMMATORY REFLEX 
Johanna Estelius 
 
Stockholm 2018 
 
 All previously published papers were reproduced with permission from the publisher. 
Cover illustration by Johanna Estelius 
Published by Karolinska Institutet. 
Printed by E-print AB 2018 
© Johanna Estelius, 2018 
ISBN 978-91-7831-031-9 
Neuroimmune mechanisms in chronic inflammation 
– Translational studies of the inflammatory reflex 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Johanna Estelius 
Principal Supervisor: 
 
Associate Prof. Jon Lampa 
MD, PhD 
Karolinska Institutet 
Department of Medicine, Solna 
Rheumatology Unit 
 
Co-supervisors: 
 
Erwan Le Maître 
PhD 
Karolinska Institutet 
Department of Medicine, Solna 
Rheumatology Unit 
 
Prof. Eva Kosek 
MD, PhD 
Karolinska Institutet 
Department of Clinical Neuroscience 
Opponent: 
 
Prof. Roald Omdal 
MD, PhD 
Stavanger University Hospital 
Department of Internal Medicine 
Clinical Immunology Unit 
 
Examination Board: 
 
Prof. Eva Sverremark Ekström 
PhD 
Stockholm University 
Department of Molecular Biosciences 
 
 
Prof. Fredrik Piehl 
MD, PhD 
Karolinska Institutet 
Department of Clinical Neuroscience 
 
 
Senior Researcher Peder Olofsson 
MD, PhD 
Karolinska Institutet 
Department of Medicine, Solna 
  
 
 
The public defence will take place on Friday the 8th of June, 2018, at 9:00 am in the Rolf Luft 
lecture hall (L1:00, Karolinska University Hospital, Solna). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The true delight is in the finding out rather than in the knowing 
- Isaac Asimov 
  
 
  
ABSTRACT 
A functional immune system is crucial for our survival from the pathogens and toxins we are 
constantly subjected to. For reasons only partially understood, in some individuals the 
immune response instead target self antigens, as suggested in rheumatoid arthritis (RA), or 
environmental non-pathogenic antigens, as suggested in allergy, leading to a failure of 
resolution and development of a state of chronic inflammation. Although current treatment 
strategies are largely effective at treating the peripheral inflammation, symptoms that can be 
attributed to the central nervous system (CNS) such as pain sensitization or fatigue often 
persist, causing considerable distress for the patient. A growing amount of evidence point 
towards that chronic inflammatory diseases are accompanied by central inflammation which 
could then be involved in driving CNS related symptoms.  
In general, the immune response may result in damage not only to the pathogen but also to 
healthy tissues in the vicinity. Therefore it is essential that an inflammatory process is 
concluded as soon as the threat is cleared. Recently, the cholinergic anti-inflammatory 
pathway (CAP) was described promoting a fast vagus mediated control of systemic 
inflammation. The anti-inflammatory potential of CAP initiated clinical trials exploring the 
use of vagal stimulation as an alternative treatment strategy for immune suppression in 
human chronic inflammatory diseases such as rheumatoid arthritis. Even so, much remain to 
be understood regarding the mechanism of CAP and its anti-inflammatory extent. 
In this thesis, work has been undertaken to explore the role of central nervous mechanisms 
in RA and seasonal allergy. Furthermore, CNS involvement in RA and other arthropaties was 
studied by mapping the cerebrospinal fluid proteome and its treatment associated changes. 
Additionally, CAP mechanisms were studied using animal models of endotoxaemia in a 
translational fashion. Whereas we could not detect an increased brain microglial activity in 
either RA or Allergy, we further confirm a state of autonomic dysregulation in RA with close 
associations to peripheral inflammation. We demonstrate for the first time that modern 
treatment strategies not only exert effects peripherally, but also lead to a central nervous 
reduction of inflammatory related proteins. We additionally identify several of these proteins 
as potentially important players to study further in the context of neuro immune responses. 
Furthermore, we provide evidence that the dependence of prostaglandins for a functional 
CAP is located to splenic events, demonstrating that prostaglandin E2 is important for 
acetylcholine production as well as immunosuppressive function in splenocytes. In addition, 
an activated CAP is shown to exert effects on additional immune cells and immune 
compartments than previously known. 
Taken together, this thesis has contributed to further our understanding of CNS involvement 
in chronic inflammatory conditions, of effects exerted by commonly used as well as 
experimental treatment strategies and neural regulation of inflammation. In the future, the 
results here presented may hopefully benefit the patient by contributing to the development 
of improved treatment strategies and better understanding of disease pathology.  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Ett väl fungerande immunförsvar är viktigt för vår överlevnad och har utvecklats för att 
skydda oss mot infektioner och skadliga ämnen i vår omgivning som vi ibland kommer i 
kontakt med. Hos vissa individer fungerar dock inte immunförsvaret som det ska utan 
reagerar på kroppsegen vävnad, vilket sker vi ledgångsreumatism. Det kan även hända att 
immunförsvaret reagerar på ämnen i omgivningen som inte utgör ett hot mot oss, t.ex. 
gräspollen hos dem med hösnuva. Detta leder till ett ständigt aktivt immunförsvar och bidrar 
till kronisk inflammation i den utsatta vävnaden. Oftast hjälper befintliga behandlingar bra, 
men symptom som har sitt ursprung i hjärnan så som trötthet eller ändrad smärtkänslighet 
påverkas inte i lika stor grad av dagens anti-inflammatoriska behandlingar. Senare tids 
forskningsrön pekar mot att det inte bara pågår inflammation i den utsatta vävnaden utan att 
mekanismer i hjärnan också kan vara påverkade hos personer med olika kroniskt 
inflammatoriska sjukdommar. Detta skulle kunna vara en av orsakerna till att hjärnrelaterade 
symptom är så svårbehandlade. 
Även hos helt friska personer är immunförsvaret ett tveeggat svärd och måste noga 
kontrolleras så att inflammatorisk aktivitet inte pågår längre än nödvändigt. Detta eftersom 
det under inflammation kan uppstå skada även på frisk vävnad. Kroppen är dock smart och 
har utvecklat en rad olika kontrollmekanismer. En av dessa kontrollmekanismer kallas 
kolinerg anti-inflammatorisk signallering (KAS) och utförs av vagusnerven som även sysslar 
med att kontrollera t.ex. våra hjärtslag eller matsmältning. En aktiverad KAS leder till att 
immunceller i mjälten hämmas i sin inflammatoriska aktivitet som annars bidrar till 
inflammation i hela kroppen. KAS fungerar därmed som en broms på immunförsvaret och 
kan på så vis dämpa inflammation. Forskare har nyligen kommit på att med hjälp av svaga 
elektriska impulser kan vagusnerven stimuleras och därmed aktivera KAS hos personer med 
kronisk inflammatoriska sjukdommar som inte svarar på befintliga behandlingar, för att på 
så vis minska deras inflammation. Trots att KAS är en relativt ny upptäckt och vi fortfarande 
inte vet allt om hur KAS fungerar eller hur bred effekt den har på immunförsvaret så har 
kliniska prövningar med elektrisk aktivering av KAS hos ledgångsreumatiker visat sig vara 
ett lovande koncept. 
Mot bakgrund av detta ämnar arbetena beskrivna i den här avhandlingen att utröna om det 
finns en aktivering av immun-påverkande mekanismer i hjärnan hos individer med 
ledgångsreumatism eller allergi och om det finns ett samband mellan dessa mekanismer och 
hjärnrelaterade symptom hos dessa patienter. Att ytterligare studera hur hjärnan påverkas av 
inflammation hos reumatiker genom att kartlägga proteiner i ryggmärgsvätska och hur de 
förändras av behandling. Och till sist att utöka förståelsen för hur KAS fungerar med hjälp av 
inflammatoriska djurmodeller. 
I denna avhandling finner vi indirekt ytterligare stöd för pågående inflammatorisk aktivitet i 
hjärnan hos reumatiker. Dessutom visar vi att det finns ett samband mellan minskad 
vagusnervaktivitet och ökad perifer inflammatorisk aktivitet vilket är i linje med tidigare 
forskningsresultat. För första gången påvisar vi även att modern antiinflammatorisk 
  
behandling, vilken har större effekt på hjärnrelaterade symptom än tidigare behandlingar, 
inte bara påverkar perifer inflammation utan även har effekter centralt i hjärnan. Vi kan även 
peka ut ett antal proteiner som är särskilt intressanta att studera vidare för att ta reda på 
deras roll vid inflammatorisk aktivitet i hjärnan och hjärnrelaterade symptom. Vi har även 
lyckats slå fast att KAS påverkar fler immunceller än vad som tidigare visats och att 
immuncellerna i mjälten är beroende av prostaglandiner, små substanser producerade i 
kroppen vid inflammation som bland annat ger upphov till feber, för att KAS-bromsen ska 
fungera korrekt.  
Sammantaget bidrar forskningsrönen från den här avhandlingen till en utökad förståelse för 
vilken roll inflammation i hjärnan spelar vid kroniskt inflammatoriska sjukdomar, hur 
moderna behandlingsstrategier påverkar hjärnan samt nervsytemets förmåga att kontrollera 
inflamation. I framtiden förväntas dessa forskningsrön att bidra till utvecklingen av nya och 
bättre anpassade behandlingsmetoder för personer med kroniskt inflammatoriska 
sjukdommar. 
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1 INTRODUCTION 
For a long period of time being diagnosed with a chronic inflammatory disease could mean a 
life in constant pain, disability and an early death. With the understanding of the concept of 
autoimmunity and development of more efficient treatment strategies a chronic 
inflammatory diagnosis in the 21st century no longer carries such burdens. However, in spite 
of an increasing amount of research being done in this field, there are still numerous aspects 
of autoimmunity and mechanisms of specific chronic inflammatory diseases that remain 
elusive. In addition, although current treatment strategies are vastly improved, they are 
sometimes expensive and may still not be able to efficiently tackle every symptom associated 
with chronic inflammatory diseases, especially symptoms related to the central nervous 
system. Consequently, hospitalization and care of patients with such diseases remain a 
considerable economic burden for society. It is therefore vital to continue research to 
improve patient quality of life as well as to reduce the burden of patient care on society. 
1.1 A BRIEF LOOK AT THE IMMUNE SYSTEM 
Throughout history, the constant arms race between host and invading pathogens has led to 
the evolution of the ever more sophisticated defence mechanisms that we today know as our 
immune system. 
1.1.1 Innate and adaptive immunity 
The immune system is generally divided into two parts, innate and adaptive immunity. The 
innate immunity is considered the main provider of a quick but unspecific first line of 
defence against invading pathogens. Adaptive immunity instead predominantly gives rise to 
a slow but highly specialised second line of defence. Adaptive immunity may also give rise to 
immunologic memory, thus providing a highly efficient counter-attack system to combat re-
infection. 
The innate immune system is comprised of several cell types e.g. neutrophils and 
macrophages, detecting threats via specific pattern recognition receptors (PRRs) such as 
toll-like receptor (TLR) family members1,2. These receptors indiscriminately recognize highly 
conserved structures on e.g. invading pathogens, so called pathogen-associated molecular 
patterns (PAMPs), e.g. lipopolysaccharides (LPS), or signs of tissue damage via damage-
associated molecular patterns (DAMPs)3. Tissue resident macrophages are usually the first 
cells to detect threats via their PRRs which may then trigger a pro-inflammatory response 
program. Circulating neutrophils and monocytes provide a reservoir of immune cells that can 
quickly be recruited to sites of inflammation to aid in the assault on the pathogen by 
phagocytosis and the release of toxic mediators such as microbicidal agents, H2O2 or NO
4,5. 
At the battlefield pathogens and resulting debris is efficiently cleared by macrophages as well 
as neutrophils4,5. The innate immune system does not only consist of cells, but is also 
accompanied by a protein based system - the complement system.  
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The complement system consists of an array of proteins with inherent proteolytic capacity, 
predominantly produced by the liver and then released into circulation 6. The proteolytic 
activity of circulating complement proteins may be triggered through three distinct 
pathways via interactions mediated by antibodies (classical pathway), lectins (lectin 
pathway) or by self activation of C3 convertase (alternative pathway)6. Activation of the 
complement system via any of these pathways promotes a cleavage cascade of the 
complement proteins into their active components 6. Some complement components (e.g. 
C1q and C4b) can attach to antigens on the surface of pathogens or damaged cells 
(opsonisation) to guide and assist clearance by neutrophils and macrophages 6. The 
complement components C5b, C6, C7 and C9 may instead together form pore structures 
known as the membrane attack complex (MAC) on the cell membrane of infected cells or 
invading pathogens, thus subjecting them to free diffusion 6,7. When enough MACs are 
accumulated on the target cell surface it can no longer cope with the stress of free diffusion 
and dies 6,7 
The adaptive immune system is primarily comprised of a group of highly specific immune 
cells where each cell may recognise a unique peptide sequence. The major players in the 
league of adaptive immunity are different subtypes of T cells and the antibody producing B 
cells. This wide selection of specificities in the adaptive immune cell pool allows immune 
responses to become tailored to different pathogens. It also provides the ability for formation 
of an immunological memory which will lead to a quicker adaptive immune response upon 
reinfection with the same pathogen8.  
The unique specificities of the adaptive immune system are mediated by B- and T cell 
receptors as well as major histocompatibility complexes (MHCs) which in humans are 
referred to as human leukocyte antigen (HLA)9. Activation of adaptive immune cells occur 
when the B- or T cell receptor recognises their specific target peptide sequence as it is 
presented on one of the two MHCs10-13. MHC-I is expressed on the cell surfaces of all kinds 
of cells in the surrounding tissues while MHC-II is predominantly expressed on specialised 
antigen presenting cells (APCs)12. Upon activation B- and T cells start to proliferate and at 
the same time undergo adaptation, a process termed affinity maturation, to fine tune its 
respective pathogen recognition and subsequent effector response 10,14,15. 
An efficient immune response where innate and adaptive immunity effortlessly work 
together is orchestrated via a host of inflammatory mediators, known as cytokines and 
chemokines, which are small proteins produced and released into the microenvironment by 
immune cells as well as cells in the inflamed or damaged tissue16.  
Although effective at keeping infection at bay, especially the inflammatory innate immune 
responses may often cause substantial damage also to healthy cells and tissues in the vicinity 
of an ongoing immune response17. It is therefore important that such inflammatory processes 
are ended as soon as the threat is neutralised to limit tissue damage and to prevent the 
development of chronic inflammatory states18. Resolution of inflammation is considered an 
active process involving a variety of mechanisms contributing to shifting a pro-inflammatory 
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microenvironment into an anti-inflammatory/healing microenvironment18. Such mechanisms 
include transformation of macrophages into anti-inflammatory/healing phenotypes, limiting 
neutrophil recruitment into inflammatory sites and their inflammatory activity, release of 
pro-resolving mediators e.g. resolvins and importantly immune suppression via neural 
pathways18. 
1.1.2 Cells of the immune system 
The cells of the immune system are produced in the bone marrow from common 
haematopoietic stem cells through a set of developmental stages termed haematopoiesis.19.  
 
Figure 1 Schematic overview of the haematopoietic development and differentiation of immune cells 
of interest for this thesis. HPC: Haematopoietic stem cell, CLP: Common lymphoid progenitor, LPs: 
Lymphoid Progenitors, CMP: Common Myeloid Progenitor, GMP: Granulocyte Monocyte Progenitor, 
RBC: Red Blood Cell, MΦ: Macrophage. Adapted from 
4,20-22
. 
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As can be discerned from figure 1 our immune system is an exceedingly complex network 
including many types of cells, each with its specialised function and responsibility, all highly 
interdependent on each other. All immune cells may be equally important since they are in 
one way or another involved in every aspect of immune responses in both health and disease. 
However, in the following section only the immune cells of particular relevance for the works 
in this thesis are briefly introduced. 
1.1.2.1 Granulocytes 
Many of the cell-types included in the innate immune system contain intracellular granules 
filled with various microbicidal agents ready to be released to the demise of any invading 
pathogen. They are therefore collectively called granulocytes and consist of neutrophils, 
eosinophils, basophils and mast cells. 
Eosinophils, basophils and mast cells are normally involved in immune responses to 
parasites by releasing various parasitocidal proteins and enzymes such as proteoglycans and 
histamine stored in their intracellular granules4,23. However, they have also been shown to 
readily produce other immunoregulatory mediators such as prostaglandins and cytokines 
indicating that they also may play a role in directing the immune response4,23,24. Eosinophils 
and basophils are recruited to inflamed tissues from the blood while mast cells are tissue 
resident cells. Interestingly, mast cells are closely involved with the nervous system and have 
been shown to express receptors for neurotransmitters e.g. acetylcholine, and can be found 
in abundance in certain areas of the central nervous system (CNS) such as the thalamus25. 
They have additionally been suggested to play a part in pain transmission 26. 
Eosinophils, basophils and mast cells also have the ability to react to immunoglobulin (Ig) E, 
the principal antibody involved in allergy and asthma27. Together with their inherent 
histamine production they are consequently highly involved in various aspects of allergy and 
asthma pathogenesis 4,23,24. 
1.1.2.2 Monocytes and Macrophages 
Monocytes are innate immune cells which circulate in the blood and upon infection migrate 
to sites of inflammation in response to interferon gamma (IFNγ). At the inflammatory site 
monocytes may differentiate and adopt characteristics of macrophages or dendritic cells 
depending on the local cytokine microenvironment 28. Monocyte derived macrophages have 
been shown to be avid phagocytosers and producers of pro-inflammatory cytokines such as 
tumour necrosis factor alpha (TNFα)28  
Macrophages residing in tissues are under normal conditions predominantly contributing to 
the maintenance of homeostasis and continuously sample the tissue in search for threats4 
Monocyte derived- as well as tissue resident macrophages are highly plastic and upon 
activation can transform into a variety of different phenotypes with specialised functions 
depending on the current cytokine environment4,20. The phenotypes are ranging in a broad 
spectrum from the classically activated pro-inflammatory (M1) macrophages producing large 
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quantities of e.g. TNFα, promoting Th1 and Th17 responses, to the regulatory IL-10 
producing macrophages and the suppressive alternatively activated anti-inflammatory (M2) 
macrophages 4,20. Macrophages are one of the cell types that transcend the boundaries of 
innate/adaptive immunity with important functions in both systems 4. Additionally, splenic 
macrophages have been shown to be essential players in neural regulation of inflammation29. 
1.1.2.3 Natural killer (NK) cells 
NK cells are important players of innate immunity, efficiently killing infected, foreign or 
tumour cells. In addition, NK cells are also avid cytokine producers and are considered an 
important source of cytokines, particularly IFNγ, in the early immune response30. The 
activation of NK cells is determined via a delicately balanced interaction of activating and 
inhibitory surface receptors that are skewed towards activation by e.g. recognition of 
infected cells31,32. Intriguingly, a potential involvement of NK cells in contributing to disease 
pathology is discussed in several autoimmune diseases including different forms of arthritis 
33-35 as well as depression36. 
1.1.2.4 CD4+ T cells 
T cells are known to be produced in the bone marrow and to continue their development in 
the thymus, entering the blood as antigen inexperienced (naïve) cells21. Following activation 
naïve cells may differentiate into their effector function and upon clearance of the threat 
most effector cells are reported to die, leaving only a small number of cells (memory cells) to 
rapidly generate an already fine-tuned response upon re-encountering the same threat37.  
T cells are generally divided based on their surface expression of CD8 and CD4 molecules38. 
CD8+ T cells display cytotoxic properties and are principally involved in immune responses 
directed toward intracellular pathogens38. CD4+ T cells may instead upon activation give rise 
to a plethora of specialized effector cells predominantly involved in different aspects 
pathogen immune responses and immune regulation39. Like for macrophage phenotypes, 
regulation of CD4+ effector T cell differentiation and subsequent function may be attributed 
to the nature of the activation stimulus and the cytokine environment39.  
Th1 cell differentiation is shown to be dependent on a cytokine environment containing IL-
12 and IFNγ21,40. Once differentiated, Th1 cells predominantly take part in combating 
intracellular pathogens by production of large quantities of IFNγ40. Elevated levels of IFNγ 
are shown to contribute to the maintenance of the response of phagocytosing innate immune 
cells20,40. IFNγ expression is mediated via the lineage specific transcription factor T-bet21.  
Th2 cell differentiation has instead been shown to be dependent on IL-4 and IL-2 in the local 
environment21,39. Differentiated Th2 cells are predominantly involved in responses against 
parasites and allergens via the transcription factor GATA3 mediated IL-4 production21,39. 
Th17 cell differentiation is furthermore shown to depend on the presence of IL-21 as well as 
IL-6, IL-23 and TGFβ21. The main effector cytokine of Th17 cells is reported to be IL-17 with 
expression mediated via the Th17 principal transcription factor RORγt21,41. Th17 cells are 
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described to be particularly adept at helping to combat fungal or extracellular bacterial 
infections21 but may also be closely linked with autoimmunity. For example, Th17 cells have 
been shown to be involved in bone destruction in an experimental model of rheumatoid 
arthritis (RA)42.  
Regulatory T cells (Tregs) are generally divided into natural Tregs developing in the 
thymus and induced Tregs developing in the periphery from ordinary naïve CD4+ T cells43. 
Tregs are principally inhibitory and are thus described to be important in suppressing illicit 
pro-inflammatory responses to self43. This inhibitory function may be exerted on the immune 
system through several processes including production of potent anti-inflammatory 
cytokines such as IL-10 and TGFβ43. Because of their important immunosuppressive 
function, dysregulation of Tregs are often ascribed as one of the contributing factors to the 
development of chronic inflammation and autoimmunity43.  
1.1.2.5 B cells 
Unlike T cells, B cells are known to undergo development in the bone marrow through a set 
of developmental stages and then migrate into lymphoid tissues44. In lymphoid tissues B cells 
mostly reside in special areas termed B cell follicles where they largely depend both upon 
having antigen transported to them and T cell help for activation44. The process of B cell 
transformation into actively antibody releasing plasma cells involves antibody class 
switching and affinity maturation and the characteristic formation of germinal centres44. 
Fully activated B cells may then respond by proliferation and production of antigen specific 
antibodies44. Like T cells, after resolution of inflammation a minority of adapted B cells are 
shown to remain to build up the memory pool45. Many autoimmune diseases, including 
arthritis, are characterised by autoantibodies46. However, the pathogenicity of the respective 
autoantibodies is not fully determined. Furthermore, B cell contribution in allergy via 
production of IgE antibodies is well established27. Consequently B cells are an important cell 
type to consider for many chronic inflammatory conditions. 
1.2 A DISTURBANCE IN THE SYSTEM - CHRONIC INFLAMMATION AND 
AUTOIMMUNE DISEASE 
To have such a delicately balanced immune system is a true evolutionary advantage to 
protect us from harm. However, the capacity for specific recognition and the ability to mount 
a perfectly tailored response to a wide variety of distinct pathogens and threats increase the 
risk of creating autoreactive immune cells47. It was long believed that it was impossible for 
the immune system to break tolerance and turn on the host48. As science progressed it soon 
became evident that even though rigorous control checkpoints are in place throughout both 
T- and B cell development, autoreactive cells may escape and in a susceptible host contribute 
to the development of autoimmunity and chronic inflammation45,49. Although the exact 
pathways leading to autoimmunity and chronic inflammation are incompletely understood 
and likely vary between diseases, several possible mechanisms for triggering cells initially 
considered non-autoreactive at the checkpoints have been suggested50. During e.g. bacterial 
infection concentration of self-antigens normally not seen in the extracellular environment 
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may become increased, often as a result of tissue damage50. In a process termed bystander 
activation, elevated levels of self-antigen coinciding with an environment of strong pro-
inflammatory signals may lead to the activation of autoreactive immune cells50 (figure 2). 
Immune cells may additionally come across pathogen derived peptides that share 
resemblance with self-peptides51. During such situations autoreactive immune cells that 
target host tissues may become activated by the cross reactive antigen and start responding 
to host tissue after clearance of the initial infection, a mechanism termed molecular mimicry51 
(figure 2). During infection with some pathogens post-translational changes of native 
proteins may be induced by the pathogen. For example, during periodontal infection with p. 
gingivalis citrullination (i.e. the enzymatic transformation of arginine into citrulline) has been 
shown to increase locally52. This process of exacerbated citrullination is discussed as one of 
the driving factors of RA development53. Such processes may lead to immune recognition of 
the same type of post-translational modification not only on the initial protein but also on 
other non-related proteins via a mechanism termed epitope spreading54.  
 
Figure 2 Examples of circumstances that may lead to activation of autoreactive immune cells during 
inflammatory events including A) Molecular mimicry and D) Bystander activation. Reprinted by 
permission from Journal of Leukocyte Biology 
55
 
Together, these mechanisms provide potential pathways where failure of resolving the 
immune response may lead to a state where the immune system is constantly triggered may 
lead to the development of various chronic inflammatory diseases such as allergy and 
arthritis. With chronic inflammatory conditions on the rise in the developed world further 
investigation into disease etiology is warranted. 
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1.2.1 Seasonal Allergy (Allergic Rhinitis) 
Seasonal allergy is reportedly increasing, reaching a prevalence of around 30% in Sweden56 
and between 10-40% world-wide 57,58, however, regional variation has been shown to be 
high59. Seasonal allergy is commonly characterised by symptoms such as sneezing, itchy eyes 
and nose and rhino conjunctivitis likely caused by local mucosal inflammation initiated by 
the inhalation of allergens58,60. Risk factors for developing seasonal allergy include both 
environmental (e.g. western lifestyle, reduced childhood infections, exposure to airborne 
pollutants and altered gut microbiota) and genetic risk factors (e.g.polymorphisms in IL-4 
and IgE receptor genes and the HLA-DR locus)61.  
Seasonal allergy is considered a Th2 driven disease mediated by defective IgE antibody 
production leading to mucosal inflammation and influx of eosinophils and basophils58,60. 
Allergens have been shown to drive differentiation of Th2 cells which via IL-4 excretion may 
promote IgE production from B cells58,60. IgE may then be captured by the numerous Fc 
receptors expressed on the surfaces of mast cells, eosinophils and basophils58,60. During 
exposure to allergen, i.e. to pollen during pollen season, the allergen can crosslink the 
surface-bound IgE on mast cells, eosinophils and basophils and may thus induce histamine 
release and an inflammatory response58,60. Developing allergy is considered a two-step 
process with a hypersensitivity reaction during the first encounter with the antigen and 
allergic response during the subsequent allergen encounters58,60. Treatment for seasonal 
allergy was long consisting only of avoiding allergen exposure and pharmacotherapy 
targeting histamine release (i.e. anti-histamines) or corticosteroids targeting local 
inflammation62. Recent advances in immunotherapy provide an attractive treatment strategy 
whereby the immune system is slowly desensitised to the allergen leaving a majority of 
subjects free of symptoms58,63. 
1.2.2 Rheumatoid arthritis (RA) 
Rheumatoid arthritis is a chronic inflammatory disease characterised by joint swelling and 
subsequent joint destruction due to synovial inflammation64. RA mainly affects the smaller 
joints in the hands although involvement of the large joints such as knees and shoulders are 
also frequent. RA is one of the more common autoimmune diseases with an overall incidence 
of 41/100,000 in Sweden and a world-wide prevalence of around 1%64-66. Autoantibodies are 
considered a frequent feature in RA, where the RA-specific anti citrullinated protein 
antibodies (ACPAs) are associated with more severe disease67,68.  
In RA, major risk factors include both genetic and environmental contributors. For example, 
a genetic risk factor attribution of about 50-60% is inferred from twin studies65. Among the 
strongest genetic risk factors associated with RA development are specific RA associated 
HLA alleles (e.g. HLA.DRB1 and PTPN22), affecting both disease susceptibility and disease 
severity65,69. Furthermore, both viral (e.g. Epstein-Barr70) and bacterial (e.g. P. gingivalis71) 
infections as well as exposure to small particular substances (e.g. textile dust72 or cigarette 
smoking53) have been reported as environmental factors contributing to the risk of 
developing RA65. Interestingly, risk factors are not fully shared between ACPA+ and ACPA- 
  9 
disease, as illustrated by the risk of cigarette smoking which is only an important risk factor 
for the development of ACPA+ RA53.  
The underlying mechanisms driving the disease are still not completely understood, but are 
gradually becoming clearer and growing evidence indicate that both innate (e.g. NK cells73) 
and adaptive (T- and B cells74,75) immune cells contribute to disease pathogenesis. 
Involvement of many pro-inflammatory cytokines such as TNFα produced by innate immune 
cells are additionally considered important69,76. It is further understood that the triggering 
event most likely takes place in the mucosal tissues and probably happen several years before 
disease onset, as a rise in autoantibody titres is detectable long before diagnosis77,78.  
Treatment strategies for RA include both pharmacological and biological approaches 
directed to immune suppression with the goal of reaching inflammatory remission and 
symptom relief. The first-line approach is the use of methotrexate, a synthetic disease 
modifying anti-rheumatic drug (DMARD). If methotrexate is found to be inefficient other 
DMARDs and biologic treatments are tried. Biologic treatments were introduced in the form 
of TNF blocking antibodies in the 90’s and to date five such biologic drugs (infliximab, 
etanercept, adalimumab, golimumab and certolizumab pegol) are available on the market79. 
These biologics have been shown to have similar efficacy in RA79. Additional biologic 
treatments include abatacept inhibiting T cell co-stimulation, tocilizumab inhibiting the IL-
6 receptor, rituximab depleting B cells and anakinra blocking the IL-1β receptor.80,81 
Furthermore, the targeted synthetic DMARDS baracitinib and tofacitinib which are 
inhibiting janus kinase (JAK), one of the key proteins in the signalling pathway of pro-
inflammatory cytokine production, have been recently added to the pool of available anti-
rheumatic drugs82. 
In addition, concomitant therapies such as corticosteroids which can be administered orally 
or locally via intra-articular injection83, pain relieving non-steroidal anti-inflammatory drugs 
(NSAIDs) such as ibuprofen as well as physical exercise are pivotal in the optimal 
management of RA. Interestingly, a higher degree of physical activity before RA diagnosis is 
likely beneficial for the outcome of the disease84.  
With all these treatments at hand severe joint destruction and deformation traditionally 
associated with longstanding RA has become a rare phenomenon. Despite the availability of 
these treatments some symptoms such as pain and fatigue remain elusive and difficult to 
treat despite being frequently reported in RA patients, although, TNF-blockade is able to 
ameliorate these symptoms to some extent85,86. 
1.2.3 Other arthropaties 
Several autoimmune diseases affecting joints exist beside rheumatoid arthritis. In this section 
the arthropaties important for the work in this thesis are briefly introduced. 
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1.2.3.1 Psoriatic arthritis (PsA) 
PsA patients show psoriatic skin involvement in addition to joint inflammation, however, 
PsA can present with a wide variety of symptoms that together with the lack of specific 
biomarkers makes diagnosis challenging87. Incidence rates of PsA of around 6/100,000 have 
been reported88. There seem to be a strong genetic component of PsA, since family history 
generates an increased risk for development of PsA, and some HLA alleles are indicated87. 
Also environmental risk factors such as viral infection are discussed, although the specific 
nature of genetic and environmental factors remains to be discovered87.  
PsA is associated with a substantial effect on the patient’s quality of life, predominantly 
attributed by the patients’ own assessment to chronic pain and fatigue89. As many as 50% of 
PsA patients have been reported to suffer from fatigue90. Together with chronic pain being a 
common feature in PsA, the need to further understand PsA pathophysiology is illustrated87. 
1.2.3.2 Ankylosing spondylitis (AS) 
In ankylosing spondylitis it is mainly the sacroiliac joints in the hip bone and vertebrae of the 
lower back that are subjected to inflammation which subsequently can lead to bone 
formation along the spine as the disease progesses91. Prevalence of AS varies substantially 
depending on country, with a prevalence reported between 0.1 and 1.4%92. Although, AS is 
generally reported more frequently in males than females a Canadian study report a recent 
increase in females diagnosed with AS93.  
AS have for a long time been known to have a genetic predisposition connected to the HLA-
B27 loci with an excess of 90% of patients being reported as HLA-B27 positive91. The 
underlying mechanisms driving AS are poorly understood. One of the possible mechanisms 
discussed is molecular mimicry between Chlamydia94 and enterobacterial95 peptides and the 
self-peptide cytokeratin96. Another possibility put forward is related to the deposition of the 
HLA-I associated molecule beta-2-microglobulin (B2M) in synovial tissues97. In this model 
increased release of B2M from AS associated HLA-B27 sybtypes in complex with peptide is 
suggested, leading to increased B2M levels which may accumulate in synovia there 
contributing to an inflammatory response97. Treatment of AS include NSAIDs as a fist-line 
strategy and when these drugs are insufficient, TNF-blockers have provided efficient 
treatment effects in a majority of patients98. 
AS is commonly associated with physical as well as centrally associated symptoms such as 
fatigue, extensive pain and depression99. In a Scottish cohort moderate pain was reported in 
70% of patients and severe pain in 15%99. In this cohort, fatigue was identified as one of five 
potentially modifiable factors contributing significantly to patient poor quality of life99. A 
study by Brophy and colleagues report that fatigue in AS is primarily associated to pain and 
that both pain and fatigue levels are reduced after initiating anti-TNF therapy100. 
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1.2.3.3 Juvenile chronic arthritis (JCA) 
While RA presents predominantly in middle aged women, Juvenile chronic arthritis is a 
heterogeneous group of diseases affecting joints in children under the age of 16 and has a 
reported prevalence of 33/100,000101. Since there is such large heterogeneity in JCA genetic 
risk factors are complex with many genes involved, but a strong association is reported to 
the HLA genes HLA-DR/DQ and HLA-DP88. Furthermore, seasonal variation in disease 
development suggests additional environmental involvement88.  
Fatigue as well as persistent pain are symptoms frequently reported also in JCA patients and 
are reported to be important contributors to a lower quality of life102. Interestingly, a 
correlation has been shown between measures of pain and fatigue in JCA102. In a study by 
Bromberg et.al. where JCA patients completed a one month symptom diary, it is revealed 
that none of the patients were completely free of pain during the study period with up to 
86% of participants reporting at least one entry of high pain103. Interestingly, there were no 
reported difference in either pain or fatigue levels between patient groups receiving biologic 
treatments compared to conventional DMARD treatment, highlighting the difficulty of 
conventional treatments to sufficiently deal with these symptoms103. 
It is important to note that although disease pathology/etiology may differ between the 
arthropaties here presented, important features such mechanisms linked to fatigue and pain 
and a substantial involvement of TNFα have been described in all of them. On the basis of 
TNF involvement in the pathogenesis of these diseases, use of TNF-blockade generally show 
good efficacy on disease progression, and CNS related symptoms such as fatigue has also 
been proven to be relieved to some extent104,105. Together this indicates a possible role of TNF 
driven peripheral and/or central inflammation in part driving CNS related pathology in these 
diseases. 
1.3 A BRIEF LOOK AT THE NERVOUS SYSTEM 
The nervous system is vital for our body to function properly. It is generally divided into the 
peripheral nervous system (PNS) including the peripheral nerves and the central nervous 
system (CNS) including the brain and the spinal cord. The peripheral nerves are either 
afferent, i.e. leading information from the periphery to the CNS or efferent, i.e. 
communicating information from the CNS to the periphery. The CNS is organised into 
different structures and brain centres each highly interconnected and each specialised at 
processing information and directing response actions regarding respective organs or 
functions 106.  
The PNS can in turn be additionally divided into two sections. The somatic nervous system 
handling voluntary movements via innervation of skeletal muscles and the autonomic 
nervous system (ANS) handling and directing involuntary bodily functions106. 
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1.3.1 The autonomic nervous system (ANS) 
The peripheral nerves of the ANS are described to innervate most of our internal organs 
including the smooth muscle cells of the heart as well as secretory glands106,107. The main 
function of the ANS is considered to be maintenance of bodily homeostasis. Typically 
homeostasis of any given organ or process is maintained by a reflex arch. The universal reflex 
arch generally consists of visceral afferent neurons together with efferent preganglionic 
neurons synapsing on post ganglionic neurons that are innervating the target organ or 
tissue106,107. The afferent neurons are able to sense the state of the organ and this information 
is then relayed to the corresponding control centres in the CNS. In the CNS the incoming 
information is processed and information about the appropriate response to take to restore 
homeostasis is communicated to the organ107. The ANS can be further divided into the 
parasympathetic nervous system (PNS) and the sympathetic nervous system (SNS)107. The 
two systems are each considered responsible for a variety of autonomic functions relating 
either to a body at rest or a body at an alerted state often termed the “rest and digest” and 
“fight or flight” responses. The PNS mainly governs rest and digest responses such as 
reduction of heart rate and release of digestive enzymes while the SNS mainly governs the 
fight or flight responses such as elevated heart rhythm and adrenaline release.  
Neurotransmitters released at nerve terminals and synapses ensure quick and accurate signal 
transduction between neurons. Acetylcholine (ACh) is the principal neurotransmitter of the 
preganglionic neural communication in both PNS and SNS, however, SNS post ganglionic 
signal transduction is mainly mediated via noradrenaline (NA) while PNS post ganglionic 
signalling continues to be principally mediated by ACh107,108. The effect of NA and ACh 
release in the target tissues can then be further fine-tuned by an array of respective receptors. 
For NA two subtypes of receptors have been described, the α- and β adrenergic receptors, 
each family consisting of further subdivisions based on receptor location, function and 
intracellular signalling pathway 107. Two families of receptors are described also for ACh, the 
nicotinic and muscarinic receptors. The muscarinic receptors are mainly found in target 
tissues where they are involved in intracellular signalling processes mediating the target 
response107. The nicotinic receptors are instead predominantly found on post ganglionic 
neurons, there important for mediating signal transduction via regulation of intracellular ion 
levels (Na+ and Ca2+)107. To maintain a tight control of the effector tissue, the 
neurotransmitters are quickly cleared after release, either by degradation (ACh) or by 
reuptake (NA) 107. 
The organs controlled by the ANS are for the major part innervated by neurons of both PNS 
and SNS origin as illustrated in figure 3. These two systems, often providing opposite 
responses, are working together in a finely balanced fashion to regulate and maintain 
homeostasis 108. 
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Figure 3 Overview of the organisation of the sympathetic and parasympathetic efferent arms of the 
autonomic nervous system with characteristic dual innervation of multiple internal organ systems. 
Parasympathetic vagus nerve (X) innervation is including the heart (8) and intestine (14). Sympathetic 
innervation is including the heart (8), intestine (14) and the spleen (10). Reprinted by permission from 
Autonomic Neuroscience
106
. 
1.3.2 Protecting the CNS 
The neurons in the CNS are largely taking care of the processes keeping us alive. For optimal 
signal transduction and functioning a highly specialised microenvironment is required. It is 
thus essential for the body to protect not only the neurons but also the CNS 
microenvironment to ensure that any of our vital functions are not compromised. 
1.3.2.1 The blood brain barrier (BBB) 
The blood brain barrier (BBB) initially evolved to provide and maintain a highly controlled 
ionic microenvironment for optimal neural communication within the CNS, and is now 
integral for maintaining CNS micro environmental homeostasis. The BBB is comprised of the 
endothelial cells, and the specialised tight junctions between them, forming the capillaries 
supplying the CNS with oxygen and nutrients. The tight junctions provide a barrier for 
larger water-soluble blood borne molecules such as cytokines as well as cells and pathogens, 
effectively blocking their entry to the CNS. The endothelial cells are in turn encapsulated by 
a layer of extracellular matrix proteins forming the basement membrane which is produced 
in part by the endothelial cells themselves and in part by astrocytes. The BBB capillary is 
then hugged by the different cell types of the CNS, primarily pericytes and astrocytes which 
are involved in regulating BBB function and permeability, but also including microglia and 
neurons. 109 
To not deprive the CNS of essential nutrients and ions required for optimal performance, 
there are a variety of BBB transport systems in place for ions and macromolecules needed by 
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the CNS. Lipid soluble molecules may however diffuse freely into the CNS across the 
endothelial cells109. Transport across the BBB of lipid mediators with poorer diffusion 
qualities e.g. being acidic, may be facilitated via active efflux carriers while larger water 
soluble macromolecules can be transported via solute carriers as well as receptor mediated or 
adsorptive mediated vesicular transport systems109,110. For example, the presence of saturable 
transportations systems across the BBB for cytokines such as TNFα as well as interferons has 
been reported111. However, some substances do not have to cross the BBB to have an effect on 
the CNS. For example, binding of some cytokines or PAMPs such as IL-1β or LPS to 
receptors on the blood facing side of the endothelial cell has been shown to induce 
endothelial cell production of small inflammatory mediators such as NO or prostaglandins 
which easily diffuse through the BBB112,113. It has also been shown that the BBB endothelial 
cells can be induced by LPS on the blood facing side to produce and release pro-
inflammatory cytokines at the CNS facing side114. Additionally, pathways for cellular entry 
across the BBB have been described including modified permeability at tight junctions 
(paracellular pathway) or directly through the endothelial cells, a process called 
diapedesis109,110. The permeability of the tight junctions of the BBB may quickly be controlled 
either by factors circulating in the blood or factors being locally produced in the CNS to 
modify entry via the paracellular pathway109,110. There are also specialised areas of the CNS 
where the permeability of the BBB is found to be increased through fenestration allowing 
larger molecules such as cytokines, or as demonstrated by Carrithers et.al lymphocytes, to 
pass through115,116. Such areas are found in the circumventricular organs and the choroid 
plexus115. BBB structure and transport systems are summarised in figure 4. 
 
Figure 4 Schematic overviewshowing blood-brain barrier structure and transport systems. A) BBB 
structure. B) Pathways across the BBB including: 1. Receptor mediated induction of polar endothelial 
cell inflammatory mediator production, 2. Transport via efflux or solute carriers, 3. Diffusion, 4. 
Receptor mediated transcytosis 5. Paracellular pathway, 6. Diapedesis. Adapted from 
109
 
There are a number of pathologic conditions where the integrity of the BBB is reported to be 
affected ranging from mild disruption (e.g. during episodes of epilepsy) to complete BBB 
breakdown (e.g. amylotrophic lateral sclerosis)109,110. Although not leading to BBB integrity 
loss, some conditions may affect the transport systems instead. One such condition is 
Alzheimer’s disease where the amyloid-β protein transport system is shown to be up 
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regulated110. Interesting to note is that certain PAMPs such as LPS and pro-inflammatory 
cytokines such as TNFα and IL-6 have been shown to be able to alter BBB 
permeability109,117,118. Consequently, alterations in BBB functionality may contribute to CNS 
inflammation and is something that should be considered for further investigation in chronic 
inflammatory conditions. 
1.3.2.2 Immunoreactive cells in the CNS 
The CNS was initially described to be an immune privileged site, where the immune system 
was denied entry due to the highly impermeable nature of the BBB. However, the CNS is not 
left unprotected and the presence of microglia cells, a CNS resident cell type with immune 
functions was described during the 1930’s by Pio del Rio-Hortega119.  
Microglia belong to the group of cells known as glial cells, whose main function is to 
maintain homeostasis in the CNS and act as supporter cells for neurons ensuring and 
maintaining appropriate neuronal function110. Microglia closely shares ancestry with 
macrophages and have been shown to arise from a common myeloid progenitor residing in 
the yolk sack during embryonic development120. During normal conditions microglia are 
predominantly present in a “resting state” where they are easily recognisable with long thin 
processes protruding from a small cellular body121. In this resting state microglia are primarily 
involved in controlling neuronal proliferation, differentiation, novel synaptic formation and 
modification of existing synapses122. In accordance with its myeloid origin microglia are also 
constantly surveying the environment for threats121. If a threat is encountered, e.g. through 
recognition via DAMPs, microglia may quickly become activated and changes phenotype to 
an amoeboid shape indistinguishable from macrophages 121 Activated microglia reportedly 
start phagocytosing pathogens and debris, excrete toxic substances such as nitric oxide and 
pro-inflammatory cytokines such as TNFα, IL-1β and IL-12 but also IFNγ to recruit more 
immune cells from the circulation and coordinate phagocytosis123. Like macrophages the 
effector function of microglia has been shown to vary depending on the stimuli and it is likely 
that a similar spectrum of effector phenotypes exist121. After an insult is cleared microglia and 
blood derived monocytes/macrophages are also found to be involved in tissue regeneration123. 
Due to their quick action and prompt inflammatory response microglia are highly involved in 
CNS pathology and are thus commonly used as markers for ongoing inflammation in the 
CNS124. Interestingly, data from in vitro as well as animal studies identify the translocator 
protein (TSPO) as upregulated primarily on microglia subjected to pro-inflammatory 
activation, and to a lower extent on astrocytes and macrophages, indicating TSPO as a useful 
marker of microglia activation125,126. This led to development of radioactive tracers directed 
against TSPO for the use of in vivo positron emission tomography (PET) imaging of central 
glia activation127. TSPO upregulation and glial activation has since been shown in a variety of 
acute and chronic inflammatory settings including peripherally induced endotoxaemia in 
non-human primates128 and humans129, human alzheimer’s disease 130, stroke in animal 
models131 and humans132 as well as experimental arthritis133. Although, microglial activation is 
gaining interest in relation to inflammatory diseases, further research is needed to fully 
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elucidate the role of microglial activation in inflammatory conditions and relations to CNS 
related symptoms and pathologies. 
Astrocytes are another type of glial cells with the ability to respond to insults134. In healthy 
CNS two phenotypes of astrocytes have been described, protoplasmic and fibrous, 
distinguished by morphology and location135. With their processes they reportedly form 
close connections to the CNS vasculature and make contact with neighbouring astrocytes 
and neurons135. Their main function at homeostasis is to supply the neurons with all the 
nutrients and components they need as well as regulating blood flow and synaptic 
transmission135. Astrocytes are shown to readily respond to injury or pathogenic derived 
threats, and like microglia responses are ranging from pro-inflammatory to anti-
inflammatory depending on strength and type of stimuli134. The inflammatory functions of 
astrocytes are not fully understood but include: 1) formation of a tight barrier creating 
containment of the affected area, thus protecting neighbouring healthy CNS tissues, and 2) 
modulation of the inflammatory response exerted by microglia and incoming immune cells 
via production of pro- or anti-inflammatory mediators such as TNFα and IL-6 or TGFβ134. 
In contrast to microglia, astrocytes (together with polydendrocytes, oligodendrocytes and 
neurons) originate from a neural progenitor22. 
It has become evident that the immune system and the CNS is intricately linked and 
immune cells are to some extent allowed to cross the BBB to perform immunosurveillance of 
the CNS, however, in a healthy state this migration is considered to be tightly controlled and 
kept at a low frequency136. Immune cells are also regularly found crossing the part of the BBB 
protecting the cerebrospinal fluid (CSF) and in CSF of healthy individuals a cell count of 
approximately 3000 cells/ml can be expected including cells of both innate and adaptive 
immunity136,137. 
1.4 NEUROIMMUNE REGULATION 
As described, the CNS is constantly subjected to immune surveillance and any subsequent 
immune responses are normally tightly controlled by the cells in the CNS. However, the CNS 
has been shown to not only have the ability control the immune system at home ground, but 
also to have the ability to regulate peripheral immune responses. This central control of 
inflammation is mainly directed via two pathways, the hormone mediated Hypothalamic-
Pituitary-Adrenal (HPA) axis and the neuronally mediated inflammatory reflex. Like big 
brother watching, having additional central control systems in place may thus provide a 
safeguard against over activation of the immune response and a prolonged state of 
inflammation. 
1.4.1 The HPA-Axis and the role of prostaglandins 
The HPA axis is a feedback regulated neuroendocrine system influencing homeostasis of for 
example digestive and cardiovascular systems via controlled release of glucocorticoids such 
as cortisol from the adrenal glands138. The glucocorticoids induced by induction of the HPA-
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axis may also exert important immunosuppressive functions138. Initiation of the HPA-axis 
involves signalling by neurons innervating the paraventricular nucleus of the hypothalamus 
resulting in the release of corticotrophin releasing hormone (CRH) and arginine vasopressin 
(AVP) into the circulation138. CRH is in turn described to act in concert with AVP on the 
pituitary gland triggering the release of adrenocorticotrophic hormone (ACTH), involved in 
the release of glucocorticoids such as cortisol from the adrenal glands138. The 
immunosuppressive properties of glucocorticoids are well established and exert its effect via 
widely expressed glucocorticoid receptors on the immune cells138. The immunosuppressive 
effects on immune cells include inhibition of pro-inflammatory cytokine release which may 
instead favour generation of anti-inflammatory immune cell phenotypes and thus promotes 
resolution138.  
It has become established that the HPA-axis may effectively be triggered by inflammatory 
mediators such as cytokines and prostaglandins139. However, inflammatory induction of the 
HPA-axis may also be provided via direct input from immunosensory afferent vagal neurons 
140 as illustrated in figure 5. Interestingly, it has been demonstrated that there may be 
dysfunction of the HPA-axis in chronic inflammatory conditions including RA where the 
amount of glucocorticoids released is not enough to counteract the ongoing inflammatory 
response141. 
 
Figure 5 Schematic overview of the HPA-axis and relation to inflammatory events. Engagement of the 
HPA-axis leads to release of glucocorticoids from the adrenal gland. Glucocorticoids feeds into the 
negative feedback loop inhibiting the HPA-axis response (pink lines). HPA axis can be initiated by 
peripheral production of cytokines in part sensed via the vagus nerve as well as via central production 
of pro-inflammatory cytokines and prostaglandins (purple arrows). Glucocorticoids additionally 
promote a shift toward anti-inflammatory cytokine production which negatively regulates the HPA axis 
response (pink lines) Adapted from 
142
 
1.4.1.1 Prostaglandins 
Prostaglandins are a group of small lipid molecules produced from arachidonic acid by a 
number of cell types and are shown to be involved in many different processes including 
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release of neurotransmitters143. They are predominantly constitutively expressed in the CNS 
and tissues, where synthesis is mainly mediated via the constitutively expressed enzyme 
cyclooxygenase-1 (COX-1)143,144. Importantly, prostaglandin production (particularly 
prostaglandin E2 (PGE2)) may readily be induced by inflammatory stimuli such as LPS or 
pro-inflammatory cytokines in a range of cells including macrophages and endothelial 
cells143,144. In such cases PGE2 production is mediated by the inducible COX-2 and 
subsequent processing by the microsomal prostaglandin E synthase-1 (mPGES-1)144,145. There 
are four receptors capable of binding PGE2 described, namely EP1-4, each with a variety of 
subtypes that may affect the response outcome146.  
Inflammatory induced PGE2 may reach the CNS, either entering via circumventricular organs 
or through induced production by BBB endothelial cells147. In the CNS PGE2 has been shown 
to be involved in induction of fever and pain responses as well as CRH release via EP3 
receptor interaction on neurons in the hypothalamus139,148,149. Prostaglandins are also shown 
to be important for the induction of “sickness-syndrome”, i.e. inflammatory mediated 
behavioural changes such as reduced food intake and reduced social encounters illustrating 
the ability of the immune system to induce behavioural changes in the host150.  
 
Figure 6 Schematic overview of prostaglandin synthesis and reported PGE2 effect on immune cells. 
Adapted from 
143,151
 
Prostaglandins may also exert direct effects on the immune cells themselves such as CD4+ T 
cells, B cells and APCs which by individual effects are seemingly driving the immune system 
toward a Th2 or Th17 response143,152. However, PGE2 mediated immunomodulation is 
exceedingly complex with sometimes opposing effects on immune cells reported. Although 
immunomodulatory effects of PGE2 is intensely studied much remain to be elucidated 
regarding mechanisms of actions152.  
In different disease pathologies, prostaglandins may have a pronounced pro-inflammatory 
role, as exemplified by Rheumatoid arthritis. In RA mPGES-1 is reported to be upregulated 
in the cells of the synovial membrane (i.e. fibroblasts and macrophages) in active disease and 
PGE2 production is readily induced by pro-inflammatory cytokines in these cells
144. 
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Exacerbated prostaglandin production in the synovium is thus thought to be one of the 
contributing factors leading to disease pathology in RA.  
Blocking prostaglandin production via specific COX2 or general COX1/2 inhibitors 
(NSAIDs) are commonly used to treat febrile, inflammatory or painful conditions146. COX 
inhibitors often provide efficient symptom relief in chronic inflammatory conditions such as 
arthritis153. However, chronic use of NSAIDs is associated with elevated risk for severe side 
effects such as gastrointestinal ulcers (though this side effect is reduced in modern selective 
COX2 inhibitors), predisposing to thrombus formation and cardiovascular events154,155. 
Together with emerging evidence that prostaglandins also may have beneficial anti-
inflammatory functions, the use of COX inhibitors may have to be re-evaluated when used as 
an anti-inflammatory treatment option146. 
1.4.2 Immunomodulation by the SNS 
To date no major parasympathetic innervation has been found reaching the primary (bone 
marrow and thymus) and secondary (spleen, lymph nodes, mucosa associated lymphoid 
tissue) immune organs.156 Instead these sites are shown to be richly innervated by NA 
releasing sympathetic neurons 156. Several studies have reported sympathetic nerve endings 
in close proximity to many types of immune cells including lymphocytes and macrophages156. 
Interestingly, in the spleen sympathetic innervation (via the splenic nerve) is highly localised 
with nerve terminals focusing in the reactive T- and B cell zones156. NA released by the 
splenic nerve may act on either α- or β NA receptors on the local immune cells. However, it is 
generally the β2AR that is expressed on immune cells and the effect of physiological NA 
concentrations on splenic immune cells has been shown to be predominantly anti-
inflammatory156. This effect includes suppression of cellular cytotoxic activity and by shifting 
cytokine production from the Th1 driving TNFα and IL-1 towards Th2 driving IL-4 and IL-
10156. 
 
Figure 7 Effects of NA engagement of α2AR or β2AR on immune cells. Adapted from 
157
. 
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LPS has been shown to induce activity in the splanchnic as well as splenic nerves generating 
an elevation of circulating levels of NA158,159. NA released by the splenic nerve has 
furthermore been shown to induce anti-inflammatory effects in activated splenic 
macrophages expressing the β2AR
160.  
1.4.3 Immunomodulation by the PNS - The vagus nerve and the 
inflammatory reflex 
As any function mediated by the ANS is generally regulated by both SNS and PNS input 
logic would dictate the presence also of parasympathetic immunomodulation.  
The largest nerve of the PNS is the Xth cranial nerve, also known as the vagus nerve, 
accounting for roughly three quarters of the parasympathetic neurons (most being afferent 
fibres) and is innervating most internal organs107,161. As the vagus is part of the “rest and 
digest” responses its main function entails inhibition of stress induced actions (e.g. to 
dampen inflammation) and induction of resting responses (e.g. decrease heart rate). In 
contrast to the SNS, post ganglionic neurons in the PNS are generally located within the 
target tissue and PNS mediated effects thus tend to be localised to the specific target 
tissue107.  
Afferent vagal neurons have been demonstrated to terminate in the nucleus tractus solitaries 
(NTS), a small nucleus in the brain stem associated with reflex control108. The central 
projections of the vagus nerve were largely elucidated in the 70’s and 80’s by a series of 
animal experiments108. From the NTS neurons project to many brain centres, including the 
hypothalamus and locus coeruleus, in an intricate network as depicted by figure 8. Efferent 
vagal outflow is primarily generated from the nucleus ambiguous and the dorsal motor 
nucleus of the vagus, both located in the caudal medulla of the brain stem108,161. Importantly, 
while no direct parasympathetic innervation to immune organs to date has been 
demonstrated, the vagus has been shown to innervate sympathetic ganglia as well as the 
adrenal gland162. This supports more indirect routes of efferent vagal immunomodulation e.g. 
mediated via controlling sympathetic innervation of immune organs or by modulating HPA-
axis output162. 
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Figure 8 Central projections of the vagus nerve in the human CNS. The afferent vagus nerve projects 
to several control centres deep in the brain including the Locus Coeruleus (LC), Thalamus (Thal) and 
Hippocampus (Hp). The efferent projections driving vagal outflow originates from structures such as 
nucleus basalis of Meynert (NBM) and Pedunculopontine tegmental nucleus (PPTg). CTX: Cortex, 
Cc: Corpus callosum, Cd: Caudate nucleus, Gp: Globus Pallidus, Msn: Medial septal nuclei, SSN: 
Superior salivatory nucleus, DRN: dorsal raphe nucleus, NTS: Nucleus tractus solitarius. Modified 
from 
163
. 
Neurons have been shown to sense and become activated by inflammatory mediators such as 
IL-1β or LPS leading to induction of sickness syndrome responses 113,164,165. Investigations of a 
neuronally mediated immune-to-brain axis of communication was initiated based on a 
growing amount of evidence showing that such neuronal functions was blockable by 
vagotomy164,165. 
Together with the finding that an inflammatory response could be abrogated by electrical 
stimulation of the vagus nerve (VNS) a reflex based model of vagal immunomodulation was 
ultimately put forward by Tracey and co-workers under the name of the inflammatory 
reflex166-168. In this model afferent vagal neurons sense peripheral inflammation and relay this 
information to the NTS where efferent vagal neurons are engaged. Efferent vagal activity in 
turn leads to an attenuation of the inflammatory response by suppression of pro-
inflammatory cytokine production by macrophages in the spleen166,167. 
1.4.3.1 Cholinergic anti-inflammatory pathway (CAP) 
By further investigations into the mechanism of the inflammatory reflex it was determined 
that its anti-inflammatory effect was mediated via ACh, since TNFα production was 
effectively reduced in endotoxaemic wild type (WT) mice but not in mice deficient in 
nicotinic α7 acetylcholine receptor (α7AChR)169,170. The efferent arm of the inflammatory 
reflex was thus named the cholinergic anti-inflammatory pathway (CAP). Further in vitro 
investigation led to the conclusion that the nicotinic receptors mediating this response was 
present on macrophages since nicotinic agonists could block TNFα release in WT but not 
α7AChR deficient macrophages169. Furthermore, important studies demonstrated a 
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dependency of the spleen for a functional CAP171,172. Splenectomy was shown to not only 
revoke induced anti-inflammatory effects of CAP, but to also be the main contributor to 
circulating levels of cytokines produced during endotoxaemia171,172. Importantly, further 
studies also showed the significance of the splenic nerve in the CAP, because by cutting it 
the anti-inflammatory properties of CAP were abolished thus demonstrating a connection 
between the PNS and SNS in regulation of peripheral inflammatory responses173. The splenic 
nerve is part of the SNS and subsequently releases NA. Macrophages are known to express 
receptors for both ACh (α7AChR) and for NA (β2AR) and both receptors have been shown 
to be able to suppress pro-inflammatory cytokine production29,168,169,174. Further scrutiny of 
the splenic events leading to attenuation of cytokine production was able to identify the 
origin of splenic ACh to a subset of CD4+ memory T cells testing positive for choline acetyl 
transferase (ChAT), the enzyme responsible for ACh production175. Rosas-Ballina and 
colleagues showed that anti-inflammatory CAP responses were un-effective in mice lacking 
these T cells, but that it can be partially restored by adoptive transfer175. Based on these 
findings, a model of CAP was presented where efferent vagal signalling initiates NA release 
in the spleen via the splenic nerve. NA engages with α7AChR on a subset of splenic memory 
T cells, which respond by upregulation of ChAT expression and ACh production. ACh in 
turn act on splenic macrophages inhibiting their production of pro-inflammatory 
cytokines175. However, the exact mechanism whereby efferent vagal signalling leads to 
splenic NA release is yet to be fully understood and alternative mechanisms have been 
suggested159. 
 
Figure 9 Autonomic control of inflammation. A) Systemic and local inflammation is controlled via 
autonomic innervation of the spleen and other organs including the intestine. Reprinted by permission 
from Immunity
176
. B) Schematic overview of anti-inflammatory effects mediated via the vagus nerve 
where efferent signalling involving the spleen represents the CAP. Reprinted by permission from 
nature neuroscience
177
. 
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The molecular events of CAP in splenocytes are comparably well established. In 
macrophages, ACh interaction via the α7AChR has been shown to affect several internal 
signalling pathways, each affecting the pro-inflammatory response to LPS. For example, 
treatment with ACh or the ACh agonist nicotine was shown to promote the ability of 
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibito (IκB) to block 
nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) mediated 
transcription of pro-inflammatory genes leading to reduced TNFα release in monocytes, and 
to limitation of leukocyte recruitment ability in endothelial cells178,179. Furthermore, 
engagement of the α7AChR is known to affect the Jak2-STAT3 signalling pathway and in 
macrophages has been shown to induce STAT3 activation leading to inhibition of NFκB 
mediated production of pro-inflammatory cytokines180,181. In addition to limiting production 
of pro-inflammatory cytokines, engagement of α7AChR has been shown to inhibit 
expression of several surface proteins involved in driving the inflammatory response in 
immune cells182.These proteins including CD14, TLR-4, intercellular adhesion molecule-1 
(ICAM-1), B7.1 and CD40, which are all LPS inducible182. It is thus indicated that the anti-
inflammatory effect extend beyond reducing splenic pro-inflammatory cytokine production, 
highlighting the need for extensive studies on CAP effects in a broader context. 
 
Figure 10 Schematic overview of intracellular signalling events leading from neuronal NA release to 
the inhibition of pro-inflammatory cytokines in macrophages. NA is released from splenic neurons 
following efferent vagal nerve activity. NA binds to β2AR on ChAT
+
 T cells which leads to upregulation 
of ChAT and subsequent increase in ACh production. Elevated levels of ACh in turn engages 
α7nAChR on macrophages initiating intracellular signalling events leading to the promotion of factors 
which inhibit NFκB mediated pro-inflammatory cytokine production. Reprinted by permission from 
BioMed research international
183
. 
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While many aspects of neuroimmune regulation via the inflammatory reflex remain to be 
studied, altogether, the CAP makes a promising pathway to target in the quest for new anti-
inflammatory treatment strategies. By better understanding the mechanism behind the 
inflammatory reflex and the CAP we may also increase our understanding of mechanisms 
leading to disease pathogenesis in chronic inflammatory conditions.  
1.5 CNS RELATED SYMPTOMS 
Apart from the disease specific symptoms, patients with chronic inflammatory disorders 
such as arthritis and allergy are often reported to suffer from more diffuse symptoms that can 
be attributed to the CNS such as altered pain perception, autonomic dysfunction, severe 
fatigue, and cognitive or mood alterations. These symptoms are often hard to treat and 
commonly the regular disease controlling treatment has little or no effect on these types of 
symptoms, causing a substantial reduction in quality of life for these patients. 
1.5.1.1 Pain  
In rheumatic disease, inflammation of the affected joint gives rise to pain and stiffness. 
Frequently the presence of pain persist in the patient despite achieving good inflammatory 
control by medication86. Generally, pain is a physiological response to harmful stimuli that 
evolved to protect us from harm. Inflammation is one of the stimuli shown able to trigger 
pain via receptors recognising pro-inflammatory mediators (e.g. cytokines or PAMPs) on 
nociceptive neurons184. An additional physiologic response of inflammatory pain is a 
sensitisation of nociceptive neurons for a period of time after the inflammatory stimulus has 
disappeared to ensure that the injured area is protected from further damage 184. This process 
of sensitisation is complex and shown to involve many mechanisms and players resulting in 
an altered pain perception controlled both locally and centrally185. Ordinarily, such adaptive 
sensitisation returns to normal after a period of time, however in some conditions this state 
of pain sensitisation may become chronic184. It has been shown that RA patients display 
altered pain perception, reacting to normally non-painful stimuli in an area unaffected by 
inflammation, typical of central sensitisation186. Together with evidence of central 
sensitisation in animal models of arthritis 187 and the reported increased incidence of 
fibromyalgia during the course of RA188 a substantial involvement of central sensitisation in 
arthritis pain pathology is suggested. However, the exact nature of events leading to pain 
sensitisation is still incompletely understood.  
1.5.1.2 Fatigue 
Fatigue is a common symptom in chronic inflammatory diseases, including arthritis and 
seasonal allergy, and is reported by patients as one of the key factors negatively affecting 
their quality of life189-192. The prevalence of fatigue is high, with reports of more than 40% of 
arthritis patients being affected and remains one of the most important symptoms in allergic 
rhinitis189,192. The mechanism(s) behind fatigue is to date poorly understood, but emerging 
evidence suggests complex interactions between a number of different factors. Studies in 
Sjögren’s syndrome suggest a genetic component as well as involvement of the IL-1β 
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system193,194. Moreover, several studies in arthritis show relationship between fatigue and 
parameters such as functional health status, mental status and level of pain85,190. In these 
studies, there was no clear relation between fatigue and systemic inflammation, however, the 
role of inflammation in fatigue is controversial and other investigations have proven that 
immune-suppressive treatments are effective to ameliorate fatigue. For example, biologic 
agents targeting TNFα have been shown to alleviate fatigue to some extent 85,195 and there 
have been additional reports of substantial decrease in fatigue following treatment with IL-
1β receptor blockade196. Furthermore, it was previously shown that elevated IL-1β levels in 
CSF of RA patients correlated positively with fatigue197. Together this indicates that 
although the pathogenesis of fatigue is multifactorial, certain inflammatory mediators may 
contribute in driving this symptom. Additionally, work by Hifinger and colleagues and 
Feldhusen et.al. shows that both country of residence and season of the year affects fatigue 
severity, demonstrating increased fatigue rate scores during wintertime and in wealthier 
countries respectively198,199. Moreover, a recent metabolomic study performed by Surowiec 
and colleagues instead show a strong association between fatigue and patterns related to 
oxidative stress200 all together shedding light on the complexity of the pathogenesis of 
fatigue. 
In allergic rhinitis fatigue is generally attributed to treatment side effects and the symptom of 
a blocked nose which is shown to severely affect sleep quality 201. However, when dissecting 
the exact nature of fatigue using multidimensional questionnaires Marshall and colleagues 
show that only mental fatigue parameters are affected in allergy, suggesting CNS 
involvement202. Further studies are thus needed to explore the connection between fatigue 
and CNS in allergy disorders. 
1.5.1.3 Altered autonomic activity 
Dysfunction of the autonomic nervous system is recognized as a trait for several chronic 
inflammatory diseases including RA203. It is well established that RA patients have an 
increased risk of early mortality due to cardiovascular events such as myocardial infarction or 
stroke which has a reported worldwide prevalence of almost 10% in RA pateints204. The 
increased risk of cardiovascular events is considered to be an effect of a dysregulation in the 
autonomic cardiovascular reflexes and heart rate variability (HRV)205. HRV is a measure of 
autonomic balance between the PNS and the SNS which can be calculated from an ordinary 
electrocardiography (ECG) recording206. Several studies confirm that not only RA patients 
and patients with other arthropaties, but also allergy patients as well as patients suffering 
from other chronic inflammatory diseases such as SLE or multiple sclerosis display 
autonomic dysfunction, although subtle differences between the diseases are reported205,207-
210. For example, RA patients are shown to have elevated basal heart rate and reduced vagal 
(parasympathetic) tone205,211. This autonomic imbalance may not only contribute to the 
increased risk of cardiovascular events, but may also contribute to the development of the 
chronic inflammatory state via impaired neuro-immunoregulatory functions212. Together this 
indicates that altered autonomic function may be connected to the inflammatory status 
rather than with any particular inflammatory disease. This has recently been reported in 
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general population where decreased parasympathetic activity associates with measures of 
systemic inflammation213. In contrast, patients suffering from allergic rhinitis is reported to 
have a dysfunction in the sympathetic regulation210. However, it is yet to be discovered what 
this means for the inflammatory status in allergy patients. 
1.5.2 The role of inflammatory mediators 
There is a growing amount of evidence pointing toward an ongoing inflammatory response in 
the CNS in both arthritis and allergy which may contribute to the development of CNS 
related symptoms and associated pathologies.  
In allergic rhinitis CNS related symptoms are well documented but poorly understood and 
have been sparsely studied202. However, emerging evidence from animal studies point 
towards CNS involvement at multiple levels of allergic rhinitis. For example, in the brains of 
allergic mice IgE and IgG levels has been shown to be elevated214. Additionally, microarray 
assessment has shown altered expression patterns of inflammation related genes in the CNS 
of allergic mice215. 
In mouse models of arthritis upregulation of pro-inflammatory cytokines in the spinal cord, 
including TNFα, IL-6 and IL-1β, is reported by several studies197,216. These cytokines together 
with PGE2 are furthermore implicated in the process of pain sensitisation
184. Additionally, 
activation of glial cells in the spinal cord has been linked to pain sensitisation via cytokine 
(e.g. TNFα) dependant mechanisms in murine experimental arthritis 217,218. Interestingly, 
experimental arthritis can be ameliorated by blocking central TNFα or IL-1β production 
indicating a strong relationship between centrally produced inflammatory mediators and 
disease pathology219,220. Furthermore, central production of cytokines and PGE2 are 
discussed in the pathogenesis of fatigue221. 
Also in a human setting involvement of inflammatory mediators in the CNS are indicated. 
For example, previous work in our group has demonstrated elevated levels of IL-1β in CSF of 
RA patients that also were shown to correlate with measures of fatigue in these patients197. 
We have also demonstrated that elevated CSF IL-1β levels is associated inversely with heart 
rate variability parameters describing autonomic function in RA patients222. Similarly, 
associations between HRV parameters and the pro-inflammatory mediators HMGB-1 and 
IL-6 has also been reported in RA patients by other investigators212,223. Intriguingly, 
functional magnetic resonance imaging studies on arthritis patients receiving TNF-blocking 
treatment furthermore reveal a normalisation of neuronal activation patterns in response to 
painful stimuli 224. Thus further strengthening the theory that (inflammatory) agents 
targeted either directly or indirectly by anti-TNF therapy is contributing to altered pain 
perception 
Together with studies investigating anti-inflammatory effects of central muscarinic ACh 
receptor engagement in a CAP context a potentially strong connection between central and 
peripheral inflammation and CNS related symptoms is implicated225 . 
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1.5.3 Vagus nerve stimulation (VNS) as a treatment strategy 
Since a suppressed or dysfunctional CAP is linked to chronic inflammatory conditions, 
treatment strategies aimed at stimulating or restoring this pathway should be able to 
alleviate disease in a significant number of patients. In light of this, electrical stimulation of 
the vagus nerve is gaining influence as a promising treatment strategy for reducing 
inflammation in chronic as well as acute inflammatory conditions. VNS by external or 
implantable devices has already been used in humans for several years for treatment of severe 
depression and drug-resistant epilepsy and is considered safe with only few side effects226,227.  
VNS has been shown to have a wide range of beneficial effects in various animal models of 
disease. For instance, in a model of colitis central activation of the cholinergic system was 
shown to decrease colitis related inflammation via pathways dependent on intact vagus and 
splenic nerve signalling as well as cellular events in the spleen228. By implantation of a 
neurostimulatory device, Levine and colleagues furthermore demonstrated that VNS is able 
to ameliorate disease severity in experimental arthritis in rats, in part via reduced systemic 
levels of pro-inflammatory cytokines229. Despite these studies being very recent, already 
implantable devices for VNS mediated activation of CAP are being tested in pilot clinical 
trials. In a study following a small group of epilepsy patients having VNS devices implanted, 
it was shown that release of the pro-inflammatory cytokines TNFα as well as IL-6 and IL-1β 
by LPS stimulation of peripheral blood cells was attenuated by CAP activation thus 
confirming the anti-inflammatory abilities of CAP in a human setting230. In the same study it 
was demonstrated that VNS by implantable devices in RA patients was able to effectively 
reduce TNFα production from peripheral blood cells as well as reducing disease activity 
scores230. A pilot trial of VNS for the treatment of patients suffering from Crohn’s disease, a 
chronic inflammatory autoimmune disease affecting the gut, has also showed good results 
with reduced measures of disease activity231. Interestingly, VNS in the Crohn’s patients was 
also shown to push HRV measures toward expected values in the healthy population231. 
Together this demonstrates the diversity of the beneficial potential of CAP activation in 
different chronic inflammatory conditions and the potential of CAP activation to be useful in 
many more diseases. However, it is also important to remember that VNS is a relatively new 
technique and we don’t yet know the consequences (beneficial or harmful) of long term 
modulation of the immune system. 
In summary, there is great interplay and interdependence between the nervous and immune 
system, a delicate balance that can become dysregulated leading to chronic inflammatory 
conditions connected with different comorbidities and CNS related symptoms. The CNS is 
thought to be a central player in contributing to this neuro-immune dysregulation and 
already neuro-immunomodulation is targeted as a successful treatment strategy in chronic 
inflammatory diseases. However, much research remains to be done to completely 
understand the inner workings of neuro-immune regulation in health and its contribution to 
disease pathologies during dysregulation. Continued research in this field is therefore of 
outmost importance to be able to efficiently and safely use current treatment strategies as 
well as developing new ones for the benefit of the patients.  
  29 
2 THE WORKS – AN OVERVIEW OF THE CURRENT STUDIES 
2.1 OBJECTIVE 
The work presented in this thesis use both human and animal settings to study different 
aspects of neuroimmune mechanisms in a translational manner. 
2.1.1 General objective of the thesis 
The overall aim of this thesis is to increase our understanding of neuroimmune 
communication and connections to CNS related symptoms in chronic inflammatory 
conditions.  
2.1.2 Specific study objectives 
1. To explore patterns of glial activation in the CNS of patients with chronic 
inflammatory conditions (RA and severe seasonal allergy) by means of positron 
emission tomography (PET) and associations to CNS related symptoms, autonomic 
activity and peripheral inflammation. (Study I and II) 
2. To evaluate the effects of anti-TNF treatment on the CSF proteome in arthritis 
patients and subsequent associations to disease activity, CNS related symptoms and 
peripheral inflammation. (Study III) 
3. To investigate the immunomodulatory effects of VNS on early immune responses by 
means of flow cytometry in a murine model of acute endotoxaemia. (Study IV) 
4. To decipher the mPGES-1 dependent prostaglandin involvement in the 
neuromodulatory ability of the CAP via VNS by in vivo/ex vivo and in vitro studies of 
murine splenocytes as well as human peripheral blood mononuclear cells (PBMCs) 
subjected to endotoxaemia. (Study V) 
By achieving these goals, small steps forward are taken on the ultimate journey leading 
towards new and/or improved treatment strategies for the benefit of patients suffering from 
chronic inflammatory diseases. 
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2.2 METHODOLOGICAL OVERVIEW 
This section is meant to provide an overview of the experimental setup used in each study. 
More detailed descriptions of the specific methods used can be found in the respective 
method section of each paper or manuscript. 
2.2.1.1 Study I 
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2.2.1.2 Study II 
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2.2.1.3 Study III 
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2.2.1.4 Study IV 
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2.2.1.5 Study V 
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2.3 METHODOLOGICAL CONSIDERATIONS 
A detailed description of the methods used will not account for the considerations relating to 
each method. In this section such considerations are discussed shedding light on current 
methodological advantages, issues and limitations. 
2.3.1 Human subjects 
In study I, II and III samples from human subjects were used. These studies were approved 
by the local ethics committee at Karolinska university hospital and subjects provided 
informed written consent. A summary of demography and characteristics of subjects 
included in these three studies are presented in table 1. 
 
RA Control Allergy Control Arthritis Control
Demographics
N 15 15 18 13 10 10
Sex (% female) 13 (86.7) 13 (86.7) 8 (44.4) 5 (38.5) 10 (100.0) 10 (100.0)
Age (median ± SD) 53 ±11.5 52 ±11.5 34 ±9.9 34 ±10.8 42 ±14.8 14.6
Diagnoses (n) ACPA+ RA (15) Healthy (15) Allergy (18) Healthy (13) RF+ RA (3)
RF- RA (2)
JCA (2)
PsA (2)
AS (1)
Psychosis (3)
Vertigo (2)
Migraine (1)
Tension 
Headhache (1)
Paresthesia (1)
Paraparesis (1)
Trigeminal 
Neuralgia (1)
TSPO genotype
High affinity binders N (%) 9 (60.0) 9 (60.0) 7 (38.9) 8 (61.5) N/A N/A
Mixed affinity binders N (%) 6 (40.0) 6 (40.0) 9 (50.0) 5 (38.5) N/A N/A
Low affinity binders N (%) 0 (0) 0 (0) 2 (1.1) 0 (0) N/A N/A
Disease characteristics
DAS28 score (median ± SD) 3.2 ±1.4 N/A N/A N/A 5.1 ±1.6 N/A
SJC (median ± SD) 1 ±3 N/A N/A N/A 4 ±5 N/A
TJC (median ± SD) 5 ±3 N/A N/A N/A 6 ±6 N/A
ESR  ≥ 20 (mm) N (%) 6 (42.9) 0 (0.0) N/A N/A 6 (60) N/A
CRP  ≥ 3 (mg/L)  N (%) 6 (40.0) 2 (28.5) N/A N/A 10 (100) N/A
Treatment
DMARD (MTX) N (%) 11 (73.3) N/A N/A N/A 10 (100.0) N/A
Biologics N (%) 12 (80.0) N/A N/A N/A 0 (0) N/A
          TNF-blocker N (%) 9 (60.0) N/A N/A N/A 0 (0) N/A
          B cell blocker N (%) 1 (6.7) N/A N/A N/A 0 (0) N/A
          T cell blocker N (%) 2 (13.3) N/A N/A N/A 0 (0) N/A
NSAID N (%) 7 (46.7) N/A N/A N/A 8 (80.0) N/A
          Daily 1 (6.7)* N/A N/A N/A 7 (87.5) N/A
          If needed 6 (40.0)* N/A N/A N/A 1 (12.5) N/A
Corticosteroids N (%) 0 (0.0) N/A N/A N/A 4 (40.0) N/A
Study I Study I I Study I I I
Table 1 Demography and baseline characteristics of study subjects included in study I, II and III
AS, Ankylosing spondylitis; CRP, C-reactive protein; DAS28, Disease activity score 28; DMARD, disease modifying anti-rheumatic 
drug; ESR, Erythrocyte sedimentation rate; JCA, Juvenile chronic arthritis; MTX, Metotrexate; NSAID, Non steroidal anti-inflammatory 
drug; N/A, Not assessed; PsA, Prosiatic arthritis; RA, Rheumatoid  arthritis; RF, Rheumatoid factor; SJC, swollen joint count; TJC, 
tender joint count; TNF, Tumour necrosis factor; TSPO, Translocator protein. * Patients were instructed not to take any NSAIDs two 
days prior to the study visit.
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2.3.2 Evaluation of patient clinical characteristics 
2.3.2.1 Disease activity  
In RA, disease activity is measured using a standardized index, the disease activity score 28 
(DAS28). DAS28 is calculated using the 28 tender joint count (TJC) and the 28 swollen joint 
count (SJC) results as well as ESR and patient global assessment (PGA)232. The cut-off 
points for disease activity characterization are classified as low (DAS28 ≤ 3.2), moderate (3.2 
< DAS28 ≤ 5.1) or high (DAS28 > 5.1) with a cut-off point of DAS28 < 2.6 considered as clinical 
remission. In this thesis, DAS28 was used for assessment of disease activity in study I and 
III. For allergic subjects in Study II asthmatic symptoms was assessed using the validated 
asthma control questionnaire (ACQ)233 and allergy symptoms were monitored by daily 
scoring of eye redness, itchy eyes, itchy nose, loss of smell, nasal congestion, runny eyes, 
runny nose, sneezing and swollen eyes during 7 days prior to the study visits. 
2.3.2.2 Health assessment questionnaire (HAQ) 
The HAQ is a validated questionnaire that in its full form covers the five dimensions of 
patient reported outcomes disability, pain, medication effects, cost of care and mortality234. 
In study III the short form HAQ only assessing disability was used. 
2.3.2.3 Pain 
There are several pain assessment methods described in the literature, including multi item 
and multidimensional tools235,236. In study I and III pain was assessed on a visual analogue 
scale (VAS). The pain VAS has been validated in RA237 and comprises an accurate and easy to 
use tool in daily rheumatologic practice as well as research. 
2.3.2.4 Fatigue 
A number of methods of evaluation have been used to investigate fatigue in chronic 
inflammatory diseases. In study I we have used the VAS assessment validated in RA238 and in 
study II we have used the validated multidimensional fatigue inventory 20 item general 
(MFI-20) 239 to evaluate fatigue. VAS fatigue provides a simple, but useful evaluation of 
fatigue. This single item scale has earlier been validated and described as more sensitive than 
longer scales240. On the other hand, the MFI-20 covers five dimensions of fatigue, namely 
general fatigue, physical fatigue, mental fatigue, reduced motivation and reduced activity 
providing an opportunity to assess different aspects of fatigue. 
2.3.3 Positron emission tomography (PET) 
Direct studies of the human CNS have historically been limited to post-mortem samples thus 
greatly restricting the types of research questions that can be asked and answered. With the 
emergence of PET in the second half of the 20th century, researchers were provided with a 
window into the brain, enabling investigation of its cerebral processes in vivo in a non-
invasive manner. In this work PET is used in study I and II to assess translocator protein 
(TSPO) binding in the brains of RA patients, allergic subjects and healthy controls. 
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Selecting an appropriate radiotracer is essential for adequate PET analysis. In study I and II 
the radioactive tracer [11C]PBR28 was used which has been shown to be upregulated on 
activated microglia in response to peripheral inflammation in both human and animal 
settings125,128,129. Importantly, [11C]PBR28 has been shown to reflect activation of peripheral 
macrophages in a model of experimental arthritis133 indicating functional use in human 
disease. In this tracer the radioactive carbon isotope 11C is incorporated into a protein that 
will bind to the peripheral benzodiazepine receptor (PBR), now known as TSPO, upon 
injection into the study participants. It has however been shown that there exist a point 
mutation in TSPO at the binding site of the PBR28 tracer, giving rise to three groups with 
different binding affinity for [11C]PBR28241. Mixed affinity binders will generate a lower 
radiation signal than high affinity binders, while non-binders will produce no detectable 
signal at all241. To compensate for binding affinity differences TSPO genotype was assessed in 
study I and II participants, and patients and controls were matched according to genotype. 
Furthermore, to protect study participants from being subjected to unnecessary risks non-
binders were excluded from participation. 
During a PET scan participants are subjected to ionising radiation which always generates a 
risk for mutagenesis, however, radiation levels in study I and II are low (equivalent of a 
year’s worth of background radiation) and well within the safety recommendations of the 
Swedish radiation safety authority. The half-life of the [11C]PBR28 traces is approximately 
20 min compared to other commonly used tracers utilising e.g. 18F which has a half-life of 110 
min242. On one hand this quick radiation decay of the [11C]PBR28 tracer is beneficial for the 
participant as that means the tracer will become harmless in the body a few hours after its 
injection. On the other hand it can cause trouble for the researchers as injection of the tracer 
must be timed precisely with its production, which takes place on site. 
The PET images are the result of radiation produced by the radioactive tracer as its emitted 
positrons decays in the target tissue in a burst of gamma radiation242. The radiation is 
captured by an array of detectors in the tomograph and by computer modelling is rendered 
into an analysable image. As with any imaging technique resolution is always an important 
issue to consider. In general PET is considered to have relatively low resolution limiting 
studies of individual small brain structures. As we were interested to study particular nuclei 
of the brainstem linked to the vagus nerve, which are small, we were unable to study them 
directly. To overcome that limitation, larger areas of interest known to be activated 
(cerebellum, insula, orbitofrontal cortex, temporal pole and thalamus) or deactivated 
(amygdala and hippocampus) by the vagus nerve were instead identified and combined 
together respectively and analysed as larger regions of interest.  
In study I and II radiation in blood samples was continuously measured at set time intervals 
throughout the 90 min duration of each PET scan. This was done since the brain is supplied 
with large quantities of blood containing circulating levels of the tracer in an intricate 
network of blood vessels, to ensure that PET image analysis is not obscured by blood borne 
tracer interference. 
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2.3.4 Heart rate variability (HRV) 
Heart rate is controlled by influences of both sympathetic and parasympathetic (vagal) 
nature. Therefore, by mathematical analysis of the distance between consecutive heart beats 
on an ECG recording, information can be inferred about HRV and the overall sympathovagal 
balance. This technique is used in study I to assess the autonomic activity in RA patients 
compared to controls. 
HRV is measured in two different domains, the time domain and the frequency domain, each 
giving rise to several parameters reflecting specific aspects of the sympathovagal balance. The 
resulting parameters and their interpretation are highly complex since many parameters are 
related to each other. To assist analysis international guidelines regarding definition of HRV 
parameters, ECG recording equipment standards and standards of presenting HRV results 
were put together in the mid 90’s 206. Although very helpful in standardizing HRV 
measurement and interpretation, the guidelines do not cover all aspects of HRV. For 
instance, the circumstances which the ECG is to be recorded under is not discussed and it is 
up to each researcher to decide what conditions best fit their setting. This has led to ECGs 
being recorded under many different conditions making it challenging to directly compare 
HRV between published studies.  
The HRV measurement is a robust strategy that has proven useful in a clinical setting e.g. to 
identify patients at risk of cardiac mortality or diagnosing neuropathies in diabetic patients 
and is also in a research setting providing substantial insight about autonomic regulation in 
health and disease206. HRV heavily rely on correct identification of individual heart beats. In 
study I the ECGs were therefore visually inspected and corrected manually to ensure that 
each heart beat is identified properly. Furthermore, ectopic heart beats and areas of 
interference was excluded which would otherwise influence the HRV outcome. 
In study I HRV measurements were calculated from 24h ambulatory ECG recordings, a 
setup used previously by our group222, which has the advantage that it minimizes the risk of 
detecting only occasional variations in heartbeat. Study participants were instructed to lead 
their lives as normal during the ECG recording sessions but to refrain from strenuous 
physical activity. Since everyone has a different life routine this may increase the variability 
of the HRV measures in our study, but in using this setup we would also get the HRV results 
giving the most truthful reflection of each person’s individual HRV measures. However, we 
have previously demonstrated that this method showed comparable results on HRV in for 
example RA with earlier studies222.  
2.3.5 Mass Spectrometry (MS) 
In study III two different MS based approaches were employed, a label-based and a label 
free approach, providing a wide protein detection range to identify as many TNF-blockade 
associated proteins in CSF of arthritis patients as possible. 
Mass spectrometry has emerged as a useful tool for analysis of complex samples such as 
biological fluids. It has undergone a rapid evolution in recent years greatly improving its 
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performance rates, including resolution and development of adequate strategies for 
efficiently coping with false discovery rates243. Like any other biological fluid, CSF is a 
complex mixture of proteins, some more abundant and some more rare. Compared to fluids 
like serum, CSF has a considerable lower protein concentration which may influence the 
number of proteins detectable and biologically important low abundance proteins may 
therefore undergo detection. However, in study III we compared our MS results with 
published data on CSF protein concentrations revealing that we are able to detect proteins 
with a concentration as low as 4 ng/ml in our material. 
It is always important to find ways to validate MS results. Since our CSF samples have been 
stored for a long time they have inevitably been subjected to some extent of protein decay. 
This is not a problem in MS since samples are trypsinated as part of the preparation process. 
However, it makes validation by common antibody based techniques such as sandwich 
based assays unreliable. In study III extensive literature studies were therefore performed 
comparing our findings to results of other human CSF proteomic studies as well as 
experimental data, ultimately confirming the reasonability and supporting the validity of our 
findings.  
2.3.6 Vagus nerve stimulation (VNS) 
Studying the mechanism and properties of the CAP in animals has been essential for 
understanding its anti-inflammatory potential and led to the development of VNS-devices 
for trial in human use in the treatment of chronic inflammatory diseases177. In this thesis the 
anti-inflammatory properties of CAP has been studied via VNS in endotoxaemic mice (study 
IV and V).  
When studying the inflammatory responses in mice (or other organisms) it is important to 
remember that there are a number of aspects that can influence their inflammatory 
responses. For instance strain differences exist, making it important to choose the 
appropriate strain for the experimental setup. In study IV we chose to work with C56BL/6 
mice. C57BL/6 mice are widely used in immunologic research and cover many well 
established disease models for numerous chronic inflammatory diseases including 
arthritis244. These mice are prone to a Th1 rather than a Th2 directed response which is 
better reflecting human arthritis considered being a Th1 driven disease69,244. Since 
prostaglandin deficiency in connection to immune regulation was to be studies in study V 
we chose to work with DBA/1lacJ mice because in this strain there was an in-house 
prostaglandin deficient mPGES-1 ko model validated in previous research245. Like C57BL/6 
mice the DBA/1lacJ strain is commonly used in immunologic research and inflammatory 
disease models are well established.  
Also external factors exist which may influence the inflammatory responses of the mice 
during experimentation. In study IV and V animals undergoing surgery were anesthetized 
by inhalation of a controlled isoflurane breathing mix. Isoflurane is known to reduce 
inflammatory responses246. To control for isoflurane effects all animals, including WT 
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controls, always underwent similar periods of anaesthesia during experimentation ensuring 
the validity of our results. Additionally, NSAIDs and other pain reducing drugs are known to 
influence the inflammatory response via effects on prostaglandin production. Since we are 
studying prostaglandin involvement in the CAP (study V) we cannot therefore administer 
these types of drugs to our animals undergoing surgery. For ethical reasons this means we 
cannot keep the animals after experimentation for extended periods of time thus limiting us 
to study short term effects in in vivo and ex vivo settings. 
Importantly, using this setup we have previously reported clear effects of LPS on cytokine 
production that is significantly attenuated following VNS in line with reports on VNS in 
severe endotoxaemia168,247. In addition, we have also tested this VNS setup in different mouse 
strains including C57BL/6 and DBA/1lacJ showing similar immune responses, indicating that 
this VNS setup in our studies are not influenced by strain differences. 
2.3.7 Flow Cytometry 
Flow cytometry is a versatile tool that has become a widely used technique in research as 
well as hospital settings aiding e.g. with diagnosis. Study IV is primarily based on flow 
cytometric analysis investigating the effects of CAP on immune cells and in study V flow 
cytometry is used to assess adrenergic receptor expression on CD4+ T cells. 
By staining a selection of antigens either on the cell surface or in the intracellular milieu by 
fluorescently labelled antibodies targeting the antigens of choice, flow cytometry allows 
recognition of multiple targets in a complex mixture of cells. Each cell in the sample is 
assessed individually for its pattern of emitted light as it passes through an array of laser 
beams and light detectors. Flow cytometry thus enables identification and subsequent 
analysis of multiple targets on the same cell as well as several parameters including relative 
number (or exact number if count beads are included in the sample) of specific subtypes or 
phenotypes of cells and their expression levels of selected antigens. 
Flow cytometry has greatly contributed to the advancement of our understanding 
particularly of the field of immunology. However, there are some technical challenges that 
should be considered for optimal performance. These include planning your antibody panel 
to avoid spectral overlap and usage of control samples to ensure proper compensation and 
gating. In most cases there will likely be some spectral overlap which has to be compensated 
for. In study IV and V single stained samples with clear positive/negative population 
distinction was used in each run to generate a high quality compensation matrix. 
Furthermore, to assist with gating fluorescence minus one (FMO) samples were always 
included for antigens with an expected pattern of continuous expression. Additionally, to 
limit unspecific binding samples were always incubated with Fc receptor blocking 
antibodies prior to staining. Study IV and V consist of pooled data obtained on different 
dates. The experiments were therefore carefully setup so that on each date there was always 
one sample per study group. 
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2.3.8 Immunofluorescence (IF) 
Like flow cytometry IF utilises fluorochrome coupled antibodies reacting to a light source. 
Similar pitfalls exist for IF regarding antibody panel selection, however, since the number of 
combined antibodies that can be used at once is greatly limited in IF, panel setup is less 
complicated. The complication may instead lay in limited availability of appropriate 
antibodies, non-specific binding and photostability of the fluorochromes used. 
Immunofluorescence has a lot in common with flow cytometry wherefore many challenges 
and limitations to consider are similar. Contrary to flow cytometry, IF allow assessment of 
individual cells in its parent tissue enabling visualisation of cell interaction and co-
localisation of expressed antigens of interest. Furthermore, IF allows assessment of cell types 
with complex morphology such as neurons as well as providing a useful alternative to 
studying antigens lacking appropriate antibodies for flow cytometry as is the case for ChAT. 
IF is used in study V to visualize and assess the in vitro expression of ChAT in splenocytes. 
2.4 STATISTICAL CONSIDERATIONS 
During the course of the PhD, the student learns about statistical methods and the 
importance of their appropriate use. Through hands on data analysis it is soon discovered 
that choosing the appropriate statistical method is not always straight forward and that 
sometimes different statistical approaches may present equally suitable tests. 
To be able to choose an appropriate statistical approach it is vital to know the characteristics 
of the data set to be analysed. This is important since different statistical tests base analysis 
on certain assumptions about the data set that needs to be met for correct analysis. 
A variety of different statistical tests, reflecting the different requirements of the hypotheses 
and data set characteristics, have been utilised in the studies encompassed by this thesis.  
 In Study I group differences were assessed by repeated measures analysis of variance 
(ANOVA) (Bonferroni corrected) or Mann Whitney U test. Associations between 
parameters were investigated with partial correlate analysis (normally distributed data) or 
Spearman correlation (non-normally distributed data). Distribution of parameters in the 
data set was assessed by Shapiro Wilk’s test of normality and visual inspection of Q-Q plots. 
In Study II group differences and the effect of pollen season was investigated by means of 
mixed effect models where TSPO genotype and sex were always taken into account as 
covariates. Normality of distribution was assessed by visual inspection of histograms. 
In Study III both univariate and multivariate analysis strategies were employed. Univariate 
analysis consisted of Wilcoxon signed rank test comparing arthritis CSF at baseline and 
after infliximab treatment. Mulitvariate approaches consisted of unsupervised principal 
component analysis (PCA) and assisted partial least squares discriminant analysis (PLS-
DA). Furthermore, associations between proteomics and clinical data were assessed by 
Spearman correlation. 
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In Study IV group differences were assessed by either Wilcoxon signed rank test (related 
data) or Mann-Whitney U test (un-related data). Normal distribution was assessed by 
Shapiro Wilk’s test of normality and visual inspection of Q-Q plots. 
In Study V group differences were assessed by one way ANOVA (Tukey’s post-hoc test) or 
student’s t-test. 
2.5 ETHICAL CONSIDERATIONS 
Throughout the PhD education we are taught the importance of considering the ethical 
implications of our work. The work that has gone into this thesis has encompassed both 
human and animal studies wherefore I find it essential, as it should be to any researcher, to 
address the respective ethical considerations.  
2.5.1 Human studies 
Although humans and animals share many physiological processes, there are also substantial 
differences that should be taken into account when translating research from animals to 
humans. Most research performed, this work included, is ultimately designed to benefit 
humankind. I therefore believe it is only fair that as much research as possible is performed 
on human subjects. Both because humans have the ability to actively choose to consent to a 
study and because the risk of studying processes and responses that are only present in 
animals is eliminated. 
Having stated this, proper care must always be taken to ensure the health and safety of the 
test subjects, and to ensure that individuals are never coerced or exploited in research. In the 
wake of the second world war global guidelines, the Helsinki declaration, was established in 
order to protect study participants in human research from unethical practices and 
misconduct. The experimental setup of any study using human participants is subjected to 
rigorous scrutiny regarding ethical considerations, necessity and potential gain of knowledge 
or benefit by an ethical committee before being allowed (or rejected).  
When recruiting participants to the studies, it is important to ensure that the individual 
considering participation is given sufficient information to be able to make a well informed 
decision before signing the consent form. Ensuring proper information and understanding of 
what participation in the study entails is also beneficial for the researcher as I believe this 
minimizes mid-study drop outs.  
Importantly, participants are always instructed that they can abort each test and withdraw 
from the study whenever they want to. Ultimately care is always taken to ensure that the 
risks of the study are outweighed by the importance of the study.  
Another thing to reflect upon is how to handle any abnormal findings of the participants 
which might need further investigation in the regular health care system. In such situations 
we made it our responsibility to refer any such individuals to experts for further testing, 
thereby enabling early discovery and treatment of disease conditions. 
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To ensure the well fare of the participants in our studies experimental procedures were 
always performed by trained and experienced personnel. To ensure that no unnecessary 
experimentation was performed, procedures such as genotyping and quick assessment of 
CRP was performed before allowing the participant to be tested. 
All studies in this work using human study participants or human samples (Study I, II, III 
and IV) are following the Helsinki declaration and was approved by the regional ethics 
committee of Stockholm, Sweden. Study subjects gave written informed consent to 
participate in these studies. 
2.5.2 Animal studies 
The work in study IV and V is predominantly based on investigations in mice. Since mice 
are not able to consent to their participation in our experimentation, considerable care is and 
must be taken to ensure the best possible well fare of the research animals. To safeguard 
animal well fare stringent systems have been put in place where all experimentation 
involving research animals must be approved by an ethical board following national and 
international ethical guidelines on animal research. All animal experimentation in this work 
was approved by the local ethics committee in Stockholm, Sweden.  
In addition, when planning the experiments the guidelines of the three R’s (replacement, 
reduction and refinement) are always kept in mind to minimize the number of animals used 
and to reduce the suffering they are subjected to. In both study IV and V we perform VNS, a 
procedure that require surgery, as well as using i.p. administered LPS to be able to study the 
mechanism of the CAP and its effect on acute inflammatory responses. The cholinergic 
inflammatory pathway is a complex structure involving many different organ systems and 
cell types 176. This makes it difficult to study the entirety of this pathway without using 
research animals, thus limiting us in the R of Replacement. Efforts have instead been made in 
the R’s of reduction and refinement to ensure maximal well fare of our animals. Even though 
the VNS surgery protocol was developed in consultation with the animal facility veterinarian 
and is performed by a skilled researcher considerable suffering for the animals is still 
associated with this technique. Firstly, to study VNS in the context of inflammatory 
responses, mice are subjected to LPS induced inflammation causing fever and flu-like 
symptoms in the animals causing them some discomfort. Secondly, we are not able to 
administer pain relief to the animals after surgery since NSAID’s and other drugs are known 
to interfere with the inflammatory responses and would thus compromise our studies. To 
reduce animal suffering experiments are always acute and animals are never kept beyond 6h 
after surgery. Moreover, before starting routine VNS experimentation the LPS dosage was 
titrated down in order to discover the lowest usable dose with a maintained readout quality 
to further reduce the discomfort of our animals. This illustrates our work to continuously 
refine our experimental models for the benefit of the research animals. Reduction can be 
illustrated in study V where VNS is mimicked by in vitro treatment with NA and other 
substances to study splenocyte responses in PGE2 deficient mice. This allows us to spare 
animals from the suffering associated with VNS. 
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The animals are kept at the animal facility at the Karolinska University hospital, Stockholm, 
Sweden in cages meeting stringent KI standards following the EU regulations regarding cage 
size, availability of food and water as well as bedding and nesting materials. Animals are 
cared for by highly trained staff and any researcher expected to work with animals are 
required to undergo extensive training. Further measures are taken such as use of protective 
gear and allowing animals to acclimatise to their new environment for at least one week 
before experimentation can start to ensure health and low stress levels in animals. 
As a researcher, it is then my responsibility to make sure that the animals I use are always 
handled with the care and respect they deserve. Therefore, I always try to handle them 
calmly, considerately, competently and quickly. 
Despite extensive guidelines being in place both for animal and human studies, ethical 
standards will always be subjective to the current societal norms. As society evolves ethical 
practices will evolve with it, and what is accepted as ethical today may very well not be so in 
the future. 
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3 RESULTS AND DISCUSSION 
3.1 STUDY I AND II 
Symptoms that can be attributed to the CNS are frequently reported in both RA and allergic 
rhinitis patients and may persist in spite of controlling the disease with medications, 
representing a considerable burden for the patient. In RA the most important CNS related 
symptoms consist of fatigue and altered pain processing, but also include altered autonomic 
activity186,189,205. In allergy the most important CNS related symptoms are related to fatigue 
191. Although the mechanisms behind these symptoms are largely unknown, a growing 
amount of evidence point toward an ongoing inflammatory response in the CNS in these 
diseases, which may drive the associated CNS related symptoms.  
In RA patients, we have previously shown elevated CSF levels of the pro-inflammatory 
cytokine IL-1β that furthermore revealed an association to fatigue measurements, indicating 
a possible connection between the two197. In allergic rhinitis, studies of CNS involvement is 
limited to animal investigations showing e.g. elevated levels of central IgE and a CNS gene 
expression pattern altered towards inflammation, indicating substantial CNS involvement 
also in allergic inflammation214,215. Interestingly, microglia activation in the spinal cord in 
response to inflammation has been shown to associate with pain sensitisation in animal 
models of arthritis217,248 and allergy249. 
In light of this, a hypothesis was put forward suggesting that compared to controls RA 
patients and allergic subjects during pollen season would show increased microglial activity 
in the CNS. We additionally sought to investigate relations between microglial activity and 
peripheral inflammation as well as autonomic activity and CNS related symptoms.  
3.1.1 No evidence of brain glial activation in either RA or allergic subjects 
To test this hypothesis a study was initiated exploring in vivo glia activation as measured by 
PET using the radiotracer [11C]PBR28 in RA patients and allergic subjects compared to 
controls. Allergy patients and their respective controls were studied both in and out of pollen 
season. [11C]PBR28 is binding to TSPO, a membrane protein which has been shown to be 
upregulated on activated glial cells in chronic inflammatory settings in both animal and 
human studies125,131,241. It should however be noted that PET scan using TSPO as a ligand is 
complex and provide several challenges. For example, the ligand binding of [11C]PBR28 is 
genetically regulated, warranting comparisons between high, mixed and low affinity binders 
respectively241. 
Contrary to our hypothesis, as shown in figure 11 no increase of TSPO expression was 
discernible in whole brain or selected brain regions of interests for either RA patients or 
allergic subjects either in or out of season as compared to controls in our studies (p>0.05).  
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Figure 11 Brain TSPO levels in A) representative RA patient and respective healthy subject and B) 
representative allergic and respective healthy subjects both in and out of pollen season. 
It has become evident that the retest performance of PBR28 is relatively high250,251 and with 
the additional need to control for variation of genetically high or mixed PBR28 binding 
affinity226 large study cohorts may be needed to generate reliable results. It may thus be 
argued that our study cohort was underpowered. However, we found similar results of no 
increased TSPO binding in RA as well as seasonal allergy, suggesting that in both these 
chronic inflammatory diseases brain glial activation, as measured by TSPO expression, may 
not be a prominent feature. A further possible confounding factor is that TSPO has been 
reported to not be exclusively expressed by microglia, but has also been detected in other 
immune responsive cells such as astrocytes and macrophages252. Interestingly, recent reports 
reveal that TSPO upregulation may be more complex than previously thought. For example, 
it has been shown that there is a discrepancy in the level of TSPO expression between 
different activation states of murine microglia with higher levels displayed in pro- than in 
anti-inflammatory microglia253. Furthermore, in some human inflammatory settings 
microglia reveal no pro-inflammatory upregulation of TSPO254. Even decreased TSPO 
expression has been reported in human pro-inflammatory macrophages, including 
macrophages derived from RA synovium255. Since the phenotype of microglia and central 
macrophages are unknown in RA and allergy this complicates the interpretation of the lack 
of TSPO increase here reported. It is however plausible that there may exist a skewed central 
microglial and/or macrophage response. In support of this animal studies have reported the 
ability of infiltrating immune cells to be able to affect microglia polarization256. In further 
support, we have previously reported that the IL-1 system is activated in RA CSF197 which 
together may create a polarizing microenvironment for driving microglia differentiation 
toward a certain phenotype. In line with this and with our current observations, PET studies 
investigating glial activation via TSPO has reported lower TSPO levels in schizophrenia, a 
neurologic condition with expected central inflammatory activation126,257. Finally, there are 
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other radiotracers in use, and an ongoing discussion on the comparable performance and 
sensitivity for detecting significant activation of microglia in different parts of the brain258. 
In conclusion, we found no increased TSPO-binding in RA or seasonal allergy which could 
indicate that brain microglia activity is not upregulated in these diseases. However, with the 
known other neuro-inflammatory features of chronic inflammatory disease and potential 
considerations with the [11C]PBR28 tracer, investigations with alternative ligands should be 
performed before excluding a role of microglia activation in central nervous mechanism of 
RA and seasonal allergy. 
3.1.2 Markers of peripheral inflammation are associated with measures of 
autonomic function in RA 
In RA patients (Study I) the peripheral cytokine levels as well as the CNS related features of 
altered autonomic activity as measured by HRV and VAS assessed fatigue was investigated. 
In study I, RA patients displayed increased peripheral levels of TNFα, IFNγ, IL-6 and IL-10 
compared to controls as shown in table 2, in concurrence with RA being considered an 
inflammatory disease259. RA patients also displayed increased levels of fatigue compared to 
controls. 
Table 2 Differences in cytokine serum levels between RA 
and HC tested with Mann Whitney U test. Values are 
presented as mean ± SD.  
    RA   HC   p 
IL-6 (pg/ml) 4.3 ± 9.4 
 
0.5 ± 0.3 
 
0.021 
IL-8 (pg/ml) 8.0 ± 3.2 8.0 ± 2.0 
 
0.993 
IL-10 (pg/ml) 0.7 ± 0.5 
 
0.4 ± 0.3 
 
0.014 
IFNγ (pg/ml) 10.4 ± 6.0 
 
6.5 ± 4.1 0.027 
MCP-1 (pg/ml) 307.9 ± 72.1 299.3 ± 89.0 0.782 
TNFα (pg/ml) 24.0  ± 30.6 2.1 ± 0.3   0.001 
HC, Healthy control; RA, Rheumatoid arthritis 
Furthermore, several significantly (p<0.05) decreased measures of autonomic activity, 
primarily in the time domain features known to be more robust during long term (i.e. 24h) 
ECG recordings, was demonstrated in RA patients in accordance with literature206,212,260. 
Contrary to our initial hypothesis, no relation was shown between brain TSPO expression 
levels and either measures of HRV, peripheral inflammation or fatigue. 
Interestingly, circulating levels of the pro-inflammatory cytokine IFNγ was shown to 
inversely correlate to root mean square of successive differences (RMSSD), a time domain 
HRV measure reflecting vagal activity (figure 12). With the close connection between the 
vagus nerve and peripheral inflammation as highlighted by the inflammatory reflex and its 
efferent cholinergic anti-inflammatory pathway261 a relation between RMSSD and IFNγ is 
thus not surprising. In fact, inverse relation between another pro-inflammatory cytokine, IL-
6, and RMSSD has previously been reported in RA212,223. Since IFNγ is primarily produced by 
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Th1 cells and to some extent by NK cells as well as microglia a question regarding their 
connection to the vagus nerve and CAP ability to influence their activity is raised, something 
that is beginning to be investigated in an animal setting in study IV.  
 
Taken together, while brain TSPO expression on microglia may not be associated with 
autonomic dysfunction, fatigue or peripheral inflammation in RA, we provide further 
evidence that there is a strong link between autonomic activity and peripheral inflammatory 
levels. Together with substantial evidence pointing toward central neuro-immune 
involvement in CNS-related features of RA, this indicates that alternative neuro-immune 
mechanisms independent of microglia activation may be at play. 
3.1.3 Markers of peripheral inflammation are elevated in allergic subjects 
both in and out of pollen season 
In Study II the peripheral cytokine levels, measures of sleep as well as the CNS related 
symptom of fatigue as measured by the validated multidimensional fatigue inventory (MFI-
20)262, was investigated both in and out of pollen season in allergic and healthy subjects. 
Allergic subjects displayed increased serum levels of TNFα and IL-5 during pollen season 
compared to controls as shown in figure 13, confirming the chronic inflammatory nature of 
allergy as described previously263. Interestingly, IL-5 serum levels were also elevated in 
allergic subjects compared to controls out of pollen season. Allergic subjects also reported 
increased sleep disturbance during pollen season, in line with litterature263, as well as shorter 
sleep time irrespective of season.  
Figure 12 Correlation plot showing 
inverse correlation between RMSSD 
measured by 24h HRV and IFNγ 
assessed by multiplex sandwich assay 
in RA patients and matched controls. 
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Figure 13 Cytokine serum levels in allergic (blue) and healthy (red) subjects in and out of pollen 
season. Dotted lines represent paired individual measures and solid lines represent group average. 
In concordance with previous studies on allergy and fatigue202, allergic subjects reported 
elevated levels of fatigue during pollen season, primarily driven by general fatigue. However, 
no relations were shown between brain expression levels of TSPO and peripheral cytokine 
levels, sleep as well as measures of fatigue, either in or out of pollen season, also in study II.  
While the exact mechanism of fatigue is unknown several possible immune-to-brain 
communication routes, including vagal signalling and HPA-axis engagement, favours 
peripheral and/or central inflammation as a highly potential driving factor264. For example, 
associations between peripheral inflammation and fatigue in cancer survivors are frequently 
reported264. Contrastingly, no relation between measures of fatigue and peripheral levels of 
cytokines was observed for allergy patients (in or out of season) in study II. However, the 
multidimensional aspect of fatigue is rarely taken into account in studies exploring relation 
to inflammation and different aspects of fatigue is likely affected differently by 
inflammation264. If fatigue is associated with central rather than peripheral inflammation, it 
is possible that such relations go undetected in this study as glial TSPO levels may not reflect 
the full spectrum of all central inflammatory events. 
In conclusion, also in seasonal allergy brain levels of TSPO may not be a feature associating 
with CNS-related symptoms (fatigue), peripheral inflammation or sleep. In light of 
numerous reports of a possible central neuronal inflammatory component in fatigue, together 
with suggestions of serotonin system involvement in allergic inflammation263, other aspects 
of brain neuro-immune involvement than microglia activation should also be explored.   
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3.2 STUDY III 
To investigate the relationship between possible central nervous inflammation in arthritis 
and CNS related symptoms from a different perspective, the proteome of CSF samples from a 
small but unique cohort of patients (n=10) with different arthropaties were analysed using 
MS. In this cohort, patients are assessed and sampled once at baseline (BL) and once eight 
weeks after initiating the anti-TNF therapy infliximab (IFX). By exploring this unique 
cohort we are thus able to ascertain IFX related changes of individual proteins detected by 
MS. This further enabled us to infer information about central inflammation and how it is 
affected by treatment, additionally shedding light on new candidate proteins to study more 
closely in relation to arthritis, inflammation and CNS related symptoms. 
3.2.1 Proteins affected by anti-TNF therapy in CSF are predominantly 
related to inflammatory processes 
Following eight weeks of infliximab treatment patients displayed significantly lower 
measurements of DAS28, levels of pain as measured on a visual analogue scale (VAS-pain) 
and peripheral inflammation (C-reactive protein (CRP) and erythrocyte sedimentation rate 
(ESR)) indicating a positive treatment response in accordance with literature265-268.  
In line with these observations univariate analysis of data from two independent MS 
experiments revealed 35 candidate proteins, a majority with immune related function, that 
were reduced in CSF of the arthritis patients following anti-TNF therapy. Further 
multivariate analysis identifies 11 of the 35 significantly reduced proteins as additionally 
significantly contributing to the separation of samples at BL and after treatment. 
Interestingly, as shown in table 3 a majority of these 11 proteins have neuro-inflammatory 
properties. In concordance with this observation, anti-TNF treatment is additionally used as 
a treatment strategy in the neuroinflammatory Behcet’s disease, where lower levels of IL-6 
are reported both in the periphery and in CSF following treatment269,270. Importantly, studies 
of anti-TNF therapy in experimental models of arthritis also indicate beneficial central 
effects on e.g. pain218,271. 
It is currently unknown if BBB function is concomitantly attenuated in arthritis. In our 
cohort of arthritis patients BBB integrity was assessed by albumin ratio and found to be 
intact. However, as elevated levels of circulating pro-inflammatory cytokines are able to 
affect the CNS via alternate routes such as the vagus nerve or via interaction with the 
endothelial cells of the BBB111,177 significant central responses are thus plausible even with an 
intact BBB. 
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Protein Name Gene Symbol Accession Fold change† Z score p value VIP p(corr) Process Suggested function(s)*
Cell Adhesion Molecule 3 CADM3 Q8N126 -0.68 -1.992 0.046 2.0 0.7 Cell adhesion Overexpressed in murine microglia after bacterial challenge and may be 
involved in development of depressive symptoms following immune 
challenge. [46]
Insulin Like Growth Factor 
Binding Protein 7
IGFBP7 Q16270 -0.50 -2.201 0.028 1.6 0.7 Cell adhesion Upregulated in spinal cord during EAE and suggested to be a regulator of 
oligodendrocyte differentiation. [57]
Protein Tyrosine 
Phosphatase, Receptor Type 
N
PTPRN Q16849 -0.49 -2.201 0.028 1.6 0.6 Cell signalling
Important for proper secretion of hormones (insulin) and 
neurotransmitters [58]
Apolipoprotein H APOH P02749 -0.32 -1.992 0.046 1.7 0.8 Coagulation May be associated with brain atrophy in healthy individuals [59]. Is the 
main antigen in antiphospholipid syndrome and may be associated with 
CNS related disease in these patients [60]
Fibrinogen gamma chain FGG P02679 -0.61 -2.201 0.028 1.5 0.5 Immune response, 
Acute phase protein
Important for proper T cell functioning and neutrophil pathogen clearance 
[40]. Regulator of microglia activation which may be important in 
pathogenesis of experimental  autoimmune encephalomyelitis [61]
Alpha-1-B Glycoprotein A1BG P04217 -0.39 -2.201 0.028 2.6 0.7 Immune response, 
Acute phase protein
-
Beta-2-Microglobulin B2M P61769 -0.44 -1.992 0.046 1.7 0.8 Immune response, 
Adaptive immuntity
Increased in circulation in chronic fatigue syndrome [62] and identified as 
important in CSF of female chronic widespread pain patients [63]. CSF 
levels of B2M is suggested to reflect immune activation and lymphoid cell 
turnover in the CNS [64]
Complement C7 C7 P10643 -0.48 -2.201 0.028 2.1 0.5 Immune response, 
Innate immunity
-
Complement Factor B CFB P00751 -0.38 -1.992 0.046 1.7 0.6 Immune response, 
Innate immunity
Differentially expressed in AD CSF [65]
Complement C4B (Chido 
Blood Group)
C4B P0C0L5 -0.37 -2.201 0.028 2.1 0.5 Immune response, 
Innate immunity
Differentially expressed in CSF of AD patients [65] and elevated in CSF of 
MS pateints with active disease [66]
Hemopexin HPX P02790 -0.33 -1.992 0.046 1.7 0.7 Oxidative stress 
protection
Neuroprotective in stroke and intracerebral haemorrhages [67]. Increase 
in CSF following yeast-induced inflammation [68]
Table 3 Proteins important for separation between patients before and after infliximab treatment. Proteins were identified in CSF of polyarthritis patients using label free proteomics and uni- and multivariate 
data analysis.
Univariate analysis
Multivariate 
analysis
† Fold change is calculated as "(sample after infliximab - baseline sample)/baseline sample" * References are refering to reference list in study III manuscript.
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3.2.2 CSF candidate proteins affected by IFX associate with clinical 
measures of inflammation and disease activity 
Although, all the infliximab reactive proteins are of considerable interest to explore further 
for their role in inflammation and arthritis, a selection was made to form the initial focus of 
investigation. Of the 11 aforementioned proteins, seven were selected based on their 
significant contribution in multivariate analysis, significant reduction by IFX and having 
known associations to arthritis for closer scrutiny with regards to relations to clinical data. 
Of these, fibrinogen gamma chain (FGG), complement factor B (CFB), cell adhesion 
molecule 3 (CADM3) and contactin-1 (CNTN-1) were found to have significant correlations 
with clinical measures of inflammation, functionality and pain. The respective correlations 
for FGG and CFB were very similar and closely followed each. The fold changes in FGG and 
CFB each correlated to the fold change in ESR as shown in figure 14 as well as fold changes 
in health assessment questionnaire score (HAQ score), a questionnaire measuring the 
functional abilities of the patients.  
 
Figure 12 Correlation plots between selected CSF candidate proteins FGG and CFB affected by anti-
TNF treatment and ESR in arthritis patients assessed at baseline (BL) and after eight weeks of 
infliximab treatment.  
Fibrinogen is normally involved in coagulation, but is recognized as a marker for 
inflammation in several chronic inflammatory diseases including RA, Alzheimer’s disease and 
multiple sclerosis272. In line with our observation of decreased FGG in arthritis CSF and 
correlation between FGG and ESR, FGG reduction has been reported in plasma of an 
arthritis patient after anti-TNF therapy273. Moreover, a neuro-immunoregulatory role for 
FGG, mediated via interaction with the macrophage antigen complex-1 (Mac-1) present on 
immune cells such as microglia, is suggested by animal experimental data274,275. The 
modulation of microglial function by blocking Mac-1 has been reported to be 
neuroprotective by inhibition of microglial H2O2 and PGE2 production respectively
276,277. In 
addition, blockade of CFB has been reported to have neuroprotective effects in a murine 
experimental model of experimental autoimmune encephalomyelitis (EAE)278. CFB is one of 
the key players in the alternative complement pathway and its expression has been reported 
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to be regulated dose dependently by TNFα in circulating human immune cells279. Thus, both 
FGG and CFB in CSF may play a possible role for central inflammatory responses and may 
therefore be involved in CNS related symptom pathology. 
Interestingly, correlations to VAS-pain were observed for both CNTN1 and CADM3. CNTN-
1 and CADM3 are both involved in cell adhesion and has both been reported in relation to 
depressive states in experimental settings280,281 demonstrating their potential for central 
effects. Importantly, in line with our observations of CNTN-1 correlation to pain, CNTN-1 
has been reported to play a role in the sodium channel Nav1.3 mediated neuronal pain 
signaling282. CNTN-1 is additionally reported to be increased in the CSF of neuropathic pain 
patients following analgesic spinal cord stimulation, further supporting the involvement of 
CNTN-1 in pain processing although the exact nature of involvement remains to be 
elucidated.  
Although using a small material the unique samples enabled investigation of the proteome in 
arthritis patient CSF for the first time, revealing that anti-TNF effects extend to the CSF 
which may help explain the beneficial treatment effects on select CNS related symptoms. 
Furthermore, we here identify FGG and CFB as potential mediators of central nervous 
inflammation, and CADM3 and CNTN-1 with possible roles in pain processing which should 
be investigated further. 
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3.3 STUDY IV AND V 
The pronounced anti-inflammatory potential of VNS together with an inability of current 
treatment strategies to sufficiently reduce disease activity in a number of patients suffering 
from chronic inflammatory diseases, including RA, swiftly initiated clinical trials to harness 
the anti-inflammatory power of CAP in such patients230. However, the exact mechanism of 
action for CAP is still being discovered and the full extent of CAP mediated effects is rarely 
studied. In study IV and V investigations into the inner workings of the CAP is initiated to 
contribute to a more complete understanding of vagally mediated neural inflammatory 
regulation. Because, by understanding the mechanism better, we enable CAP activation to be 
used more efficiently and to its full potential as a treatment strategy in patients likely in a 
plethora of different inflammatory settings.  
3.3.1 VNS decrease CD69 expression in CD4+ T cells and NK cells in spleen 
of endotoxaemic mice without apparent effects of cell trafficking 
(study IV) 
In our setup of VNS in endotoxaemic mice, a clear anti-inflammatory effect was observed 
with significantly decreased levels of TNFα as well as IFNγ in VNS compared to Sham 
animals in accordance with the pivotal CAP study by Borovikova et.al.168. In the present 
experimental setup cells were collected 6h after VNS or Sham surgery limiting us to study 
the early inflammatory responses. 
The bacterial endotoxin LPS, is known to induce a clear activation of immune cells resulting 
in avid cytokine production both in mice and men283. In accordance, we observe a clear 
increase in CD69 in both NK and all T cell subsets in groups receiving LPS compared to 
control groups not receiving LPS, indicating a LPS driven immunoreactivity in our model.  
Populations of different immune cell types of both innate and adaptive origin were identified 
by commonly used extra- or intracellular markers. While both relative and absolute cell 
numbers remained largely constant in identified cell populations indicating little effect of 
VNS on cell trafficking, CD69 expression was readily reduced by VNS in both splenic and 
circulating CD4+T cells. As shown in figure 15, when dissecting the contribution of different 
CD4+T cell phenotypes or subtypes to this observation, it was revealed that VNS mediated 
decrease in CD69 extend to T cells of both memory and naïve phenotype but not regulatory 
T cells or Th17 cells although a tendency was observed in Th1 cells. In blood CD69 reduction 
in VNS groups is largely reflecting observations is spleen. Interestingly, also splenic NK cells 
displayed reduced CD69 expression in the VNS group compared to sham, an effect that was 
not extended into blood (figure 16). It will thus be interesting to explore what CAP 
mediated CD69 reduction means in terms of functionality of the affected cells.  
Interestingly, we report similar tendencies of decreased CD69 expression in T cells also in 
the mesenteric lymph nodes (MLN). In contrast to the observations in spleen and blood a 
significant increase in relative CD4+ T cell numbers was observed in MLNs indicating that 
cells T cells may be sequestered there and illustrating that CAP effects may be organ specific.  
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Figure 13 CD69 surface expression as measured by flow cytometry on T cell subsets from C57BL/6 
endotoxaemic mice 6h following VNS or Sham surgery. Sham treated animals not receiving LPS 
(Sham no LPS) and untreated animals (WT) were used as control groups. A) Representative 
histograms of CD69 staining in spleen (left) and blood (right). B) Geometric mean fluorescence 
intensity (MFI) of CD69 in CD4 T cells (CD4
+
), CD4 memory T cells (CD4
+
, CD44
high
, CD62L
low
), CD4 
naïve T cells (CD4
+
, CD44
low
, CD62L
high
), regulatory T cells (CD4
+
, FoxP3
+
), Th1 cells (CD4
+
, IFNγ
+
) 
and Th17 cells (CD4
+
, IL-17
+
). Each dot represents one animal. * indicates p<0.05. 
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Figure 14 Surface expression of CD69 as measured by flow cytometry on non-T cells from C57BL/6 
endotoxaemic mice 6h following VNS or Sham surgery. Sham treated animals not receiving LPS 
(Sham no LPS) and untreated animals (WT) were used as control groups. A) Representative 
histograms of CD69 staining in spleen (left) and blood (right). B) Geometric mean fluorescence 
intensity (MFI) of CD69. Each dot represents one animal. * indicates p<0.05. 
The efficacy of VNS to limit pro-inflammatory cytokine production is well established in 
both human and animal models168,230. However, only Mihaylova and co-workers have so far 
investigated the effect of VNS on immune cells in a broader perspective, reporting no effects 
on cell trafficking284, further supporting our observations. Contrasting to our observations of 
VNS mediated reduction of CD69, Mihaylova et.al. detects no effect of VNS on cell 
activation284. Several reasons for this discrepancy may be related to differences in 
experimental setup between our two studies. First, Mihaylova’s study is conducted in rats 
and although mice and rats are closely related, species differences may exist. Secondly, a 
higher dose of LPS is used in Mihaylova’s study, which may overpower the VNS ability to 
fine tune the immune response. Third, and most importantly, whereas Mihaylova and 
colleagues use CD134 as a marker of activation, CD69 is used in our study. While CD69 
upregulation is reported to be detectable already 1h after activation with full expression 
plateauing around 6h, CD134 upregulation after activation may take up to 12h, but can be re-
expressed in memory subsets as early as 1h after activation285,286. The different temporal 
dynamics in expression pattern after activation, may thus explain why we are able to observe 
VNS effects on activation in contrast to Mihaylova’s study.  
Finally, study IV show for the first time that CAP effects extend also to NK cells. NK cells 
are not only important for cell mediated killing, but may also be key players in directing both 
T and B cell responses and have gained interest as mediators in several autoimmune diseases 
including rheumatoid arthritis287. In RA an accumulation of primarily cytotoxic NK cells are 
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found in the synovial fluid, where these cells are reported to express increased levels of CD69 
and produce greater amounts of pro-inflammatory cytokines compared to their circulating 
counterparts287. Accumulation of such NK cells may thus be contributing to the pro-
inflammatory environment in the arthritic joint. This is further supported by an 
experimental animal model of arthritis reporting beneficial effects of NK cell depletion on 
bone erosion and arthritis severity287. However, it is important to note that the nature of NK 
cell involvement may be beneficial since NK depletion has also been reported in 
experimental arthritis to exacerbate disease and autoantibody production287. 
In light of this, activation of CAP to may therefore be beneficial in inflammatory conditions 
where dysactivation of NK cells is driving pathology.  
3.3.2 The anti-inflammatory potential of CAP is dependent on functional 
PGE2 synthesis in murine and human immune cells subjected to 
endotoxaemia 
In a previous study from our group it was revealed that CAP in PGE2 deficient mPGES-1 ko 
mice were unable to reproduce the evident anti-inflammatory effects seen in mPGES-1 wt 
counterparts245. There are several steps in splenic events of the CAP response where PGE2 
involvement may play an important role, including NA release, β2AR expression and 
synthesis of ACh. In study V PGE2 involvement is therefore investigated in each of these 
steps. 
The first two steps of splenic events following initiation of CAP is NA release into the spleen 
mediated by splenic nerve activity and engagement of β2AR on ACh producing T cells of 
memory phenotype177. Signaling in the splenic nerve has been shown to be initiated also by 
peripheral LPS and to depend on central PGE2 involvement
158. Since mPGES-1 deficiency 
display reduced PGE2 levels in the CNS, NA release in the spleen may be affected in mPGES 
ko mice although anti-inflammatory signaling in the splenic nerve in this study is mainly 
attributed to VNS. PGE2 is also an important modulator of T cell activation, differentiation 
and function288, wherefore PGE2 deficiency may affect splenic T cell β2AR expression or 
functionality. However, as shown in figure 17 NA release was found to be increased after 
VNS in both mPGES-1 ko and wt mice. Furthermore, β2AR expression as well as relative cell 
numbers of CD4+ T cell memory, naïve and effector subsets were normal following VNS in 
both mPGES-1 ko and wt mice. PGE2 mediated NA and β2AR deficiency as the reason for 
impaired CAP in mPGES-1 ko mice was thus ruled out. It is important to point out that 
while β2AR expression was normal on splenic CD4+ T cells, we are not able to disclose if its 
function is normal in mPGES-1 ko mice. 
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Figure 15 Noradrenaline measured in spleen extract of mPGES-1 ko and wt mice subjected to VNS 
or sham surgery following i.p. LPS (2mg/kg). 
In vitro studies of splenocytes from mPGES-1 ko and wt mice reveal intact ability of both ko 
and wt splenocytes to produce pro-inflammatory cytokine in response to LPS. However, the 
anti-inflammatory effect of NA treatment, mimicking splenic nerve signaling, was observed 
in mPGES-1 wt splenocytes but impaired in mPGES-1 ko splenocytes. Thus, it is indicated 
that PGE2 dependence is mediated at a cellular level. With the knowledge that immune cells 
must depend on upregulation of the ChAT enzyme for their ACh production289 and LPS 
treatment is known to induce ChAT expression in immune cells290 PGE2 may affect this 
process. As shown in figure 18 mPGES-1 ko and wt derived splenocytes displayed similar 
levels of ChAT expression during unstimulated conditions. However, when splenocytes 
were stimulated with LPS an increase of ChAT expression was seen in mPGES-1 wt but not 
ko derived splenocytes. Thus the PGE2 dependent step in the anti-inflammatory response of 
CAP is attributed to ChAT induction. In accordance, studies of a human T cell line report 
induced ACh synthesis via ChAT expression instigated by engagement of prostaglandin 
receptor EP4291. This illustrates that a role for PGE2 in mediating a proper anti-inflammatory 
CAP response upon VNS could be important also in a human setting. 
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Figure 16 ChAT expression in splenocytes from mPGES-1 ko and wt mice after 20h in vitro exposure 
to LPS (10ng/ml). A) Representative images of immunofluorescent staining of ChAT (green) and DAPI 
(blue) of cultured mPGES-1 ko and wt splenocytes. B) Quantification of ChaT expression in LPS 
treated or unstimulated mPGES-1 ko or wt splenocytes. 
 
Importantly, engagement of the cholinergic receptor α7nAChR is not only an integral part of 
the CAP, but has been shown to diminish pro-inflammatory cytokine production of immune 
cells in both human and animal settings in its own right292,293. In line with this, a nicotine 
mediated inhibition of pro-inflammatory cytokine production in response to LPS was 
demonstrated both in mPGES-1 wt splenocytes and human PBMCs (figure 19). This anti-
inflammatory response was not seen in mPGES-1 ko splenocytes and was abolished in 
human PBMCs after pharmacologic blockade of PGE2 synthesis.  
 
Figure 17 TNFα release in splenocytes treated with nicotine under endotoxaemic condition. A) 
Percent decrease of TNFα in nicotine pre-treated condition vs LPS only in mPGES-1 ko and wt 
mouse splenocytes. B) TNFα release measured in supernatant from cultures of human PBMCs pre-
treated with nicotine and stimulated by LPS in conditions with and without mPGES-1 inhibitor. 
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Together, these results indicate that PGE2 may be important for proper CAP-mediated anti-
inflammatory regulation at the level of ACh production as well as α7nAChR dependent pro-
inflammatory cytokine regulation. These results furthermore illustrate that the PGE2 
dependence is also present in humans warranting careful consideration of NSAIDs in 
persons depending on the anti-inflammatory properties of CAP.  
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4 GENERAL DISCUSSION 
Several routes whereby the CNS can be made aware of peripheral inflammation, including 
afferent vagus nerve signalling and cytokine meditated prostaglandin production at the BBB 
interface, has been discovered in recent years147,177. Together with the discovery of active 
neuronal control of inflammation via the vagus nerve in the form of the CAP177 it was 
established that the CNS plays an important role in directing inflammatory responses. 
Intriguingly, animal studies of vagotomy show reduction in the production of pro-resolving 
mediators and a delay of resolution294 further strengthening the importance of functional 
vagal signalling to properly control inflammation. In light of this, it is interesting to note that 
autonomic activity is often reported to be altered in different chronic inflammatory 
conditions which may contribute to a dysregulated immune response perpetuating 
inflammation. In RA patients, measurements of HRV reveal a consistent reduction in 
parasympathetic (vagal) signalling211 which was also observed in our patients in study I. The 
close connection between vagal signalling and peripheral inflammatory mediators is 
illustrated by a frequently reported inverse relationship between HRV measures and 
peripheral HMGB1, IL-6, IL-8, IL-13 as well as IL-10 levels in inflammatory conditions such as 
RA212,223, encephalopathy in newborns295, sepsis296, cardiovascular disease297 and type-1 
diabetes298. While the HRV relation to IL-6 is reported in multiple conditions, the HRV 
relationship to other cytokines may be disease specific reflecting the inflammatory nature of 
the respective diseases. In study I we report a similar relationship between autonomic 
activity and IFNγ. In support of this, data from animal sepsis studies report that LPS 
administration induced a reduction in HRV which was related to increased peripheral 
cytokine levels299. Interestingly, mouse studies of pulmonary inflammation, known to be 
associated with altered breathing patterns (i.e. altered autonomic activity), identifies a 
connection between elevated TNFα and IL-1β levels in lung and elevated IL-1β levels in the 
NTS, the primary brainstem nucleus controlling vagal signalling 300. Interestingly, Ek et.al. 
has previously shown that neurons terminating in the NTS are highly responsive to 
peripheral IL-1β301. Together this underscores the potential involvement of central nervous 
inflammation in autonomic functionality in particular and CNS related symptoms in general.  
Supporting this notion, we have previously reported elevated central cytokine levels in both 
RA patients and experimental arthritis models and shown that CSF cytokine profile differs 
between RA (IL-1β) and fibromyalgia (IL-8) patients197,222. Interestingly, the source of CSF 
IL-1β was indicated to be locally produced in the CNS since CSF levels was found to exceed 
plasma levels197. The central cytokine profile of allergic subjects remains unknown. However, 
both IL-6, TNFα and IFNγ were detectable in CSF of allergic patients with different types of 
cognitive impairment although no differences were observed in cytokine levels compared to 
non-allergic cognitively impaired subjects302. 
Pain sensitisation which is one of the CNS related symptoms frequently associated with RA 
and other arthropaties has been found to be connected to microglia as well as astrocyte 
activation in the spinal cord in several models of experimental arthritis217,218,248. It has further 
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been shown that inflammatory mediators such as prostaglandins and TNFα are closely 
linked to microglia associated pain217,218,303. Interestingly, a recent report by Yamasaki and co-
workers suggest that similar actions may be seen also during allergy. They similarly 
demonstrate an activation of astrocytes and microglia in spinal cord of allergic mice relating 
to allodynia, furthermore describing a shift in spinal microglia phenotype toward pro-
inflammatory M2 in the allergic mice249. Activated microglia has been shown in various 
animal and experimental models to play an important part in CNS cytokine production as 
well as behavioural changes such as infection driven delirium304.  
Microglial activation detected by PET has been shown to be induced by peripheral 
inflammation129 and is reported in a growing number of acute and chronic inflammatory 
conditions such as stroke132, Alzheimer’s disease130 and multiple sclerosis305. Since activated 
microglia are a considerable source of cytokines in the CNS306 they are likely important 
players involved in CNS-related pathology in chronic inflammatory diseases. 
However, we found no relation between HRV and glial activation as assessed by central 
TSPO levels in either RA (Study I) or allergy patients (Study II). Recent contradictory 
reports of reduced central TSPO levels despite evidence of elevated central cytokine levels in 
schizophrenia patients initiated a suggestion by Notter and colleagues that TSPO may not 
accurately reflect low grade central inflammation126. Such a theory seems likely considering 
the high plasticity of microglial phenotypes and their strong dependence on 
microenvironmental ques to direct differentiation and thus their response. The nature of the 
potentially disease specific central cytokine profile222 may therefore also contribute to the 
discrepancy in microglial TSPO response. This may provide an explanation for the lack of 
association between central TSPO levels and CNS related symptoms observed in study 1 and 
II. However, in support of our results, a study in an allergic mouse model report decreased 
microglial activation and increased neurogenesis in hippocampus of allergic mice307 
suggesting that there may indeed be no association between central glial activation and 
allergy or RA.  
It is however conceivable that also other centrally induced/elevated mediators exert 
substantial effects on central inflammation and CNS related symptoms. As shown in study 
III several proteins related to inflammatory processes identified in CSF of arthritis patients, 
including fibrinogen gamma, was shown to be down regulated after TNF-blockade. 
Fibrinogen gamma was shown to be related to the reduction in peripheral inflammation. The 
vagus nerve also innervates the liver, the principal site of production of fibrinogen, and has 
there been reported to exert anti-inflammatory effects after VNS176. Whether or not this anti-
inflammatory effect extends to fibrinogen production is unknown, however a hint is 
provided by Carney et.al and Cooper et.al. They report an inverse relationship between HRV 
and peripheral fibrinogen levels in general population308 and in coronary heart disease 
patients with depression309 respectively. In line with this, elevated levels of circulating 
fibrinogen are reported in arthritis310. Whether elevated peripheral levels of fibrinogen are 
reflected in the CSF of arthritis patients remains unknown. However, as CSF fibrinogen 
gamma levels are reducible by TNF-blockade (study III) it is conceivable. We suggest a role 
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for central FGG in modulating central inflammation in accordance with reports of FGG 
involvement in microglial activation via MAC-1 complex in an EAE model311.  
Although a successful treatment strategy, TNF-blockade and other biologic treatments are 
not able to help all patients and symptoms may persist. Together with the conceivable risk of 
the patient developing anti-drug antibodies312 there is a need for the development of 
alternative treatment strategies. One such promising alternative is activation of the CAP via 
VNS, which has been proven effective in mouse models of e.g. sepsis, RA, colitis and 
postoperative ileus229,313-315. Autonomic dysregulation is described in many patients with 
different chronic and acute inflammatory disorders including RA205, systemic lupus 
erythematosus316, allergy317 and sepsis296. In RA, autonomic dysfunction is characterised by 
decreased vagal signalling205, indicating that the CAP in these patients may also be impaired 
and may thus contribute to the exacerbated inflammation. Activation of the CAP in RA 
patients via VNS could then provide an important tool to restore autonomic function to a 
certain extent and provide increased ability for neuro-immunoregulation. Intriguingly, pilot 
clinical trials are showing promising results in RA and Crohn’s disease with indications also 
in postoperative ileus230,231,315. However, a lot remain unknown regarding the exact 
mechanism and extent of the CAP mediated anti-inflammatory properties as illustrated by 
the failure of VNS to reduce inflammation in human endotoxaemia318. Therefore it is 
important to continue to explore the mechanism and effects of CAP to ensure continued safe 
and optimal use of VNS as a treatment strategy. 
As the CAP is increasingly investigated, a growing amount of studies report CAP effects 
beyond reduced pro-inflammatory cytokine production from macrophages in the spleen. For 
example, vagal projections to the gut are found to influence muscularis macrophages via 
enteric neurons in a mechanism independent of the spleen319. Furthermore, CAP has been 
shown to affect expression of the surface adhesion protein CD11b on endothelial cells 
reducing leukocyte migration320. In line with this, in study IV we extend the observations of 
VNS mediated effects to reduction of CD69 expression on NK cells in spleen and effects on 
CD4+ T cell trafficking in the MLN. Additionally, in study V a prostaglandin dependence for 
intact anti-inflammatory effects on pro-inflammatory cytokine production is demonstrated, 
together adding to the constantly broadening scope of CAP mediated effects to consider in 
therapeutic settings. 
Emerging evidence point toward an additional role for VNS in central inflammation and the 
control of cognitive function. Meneses and co-workers for instance describe a role for VNS in 
neuronal inflammation, where central cytokine levels and microglial activation as measured 
by Iba-1 expression is attenuated by VNS in a model of intrathecal endotoxaemia321. In line 
with this, VNS has also been shown to reduce inflammatory mediated recruitment of 
neutrophils into areas of the CNS with BBB fenestration, thus controlling pro-inflammatory 
cytokine levels in the brain322.  
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Together these data highlight the extensive ANS involvement and detrimental impact of 
ANS dysregulation in the control of inflammatory responses. The potential contribution of 
neuroinflammation on burdensome CNS-related symptoms and the importance of continued 
investigation into all these aspects of neuroimmune mechanisms in chronic inflammatory 
disease conditions. 
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5 CONCLUDING REMARKS 
With chronic inflammatory conditions being a considerable burden for society as well as the 
patient it is essential to make every effort to better understand the underlying disease 
pathology. The work of this thesis has investigated the role of central inflammation in disease 
pathology and connection to CNS related symptoms as well as explored mechanisms of 
neuroimmune regulation. 
Based on evidence pointing toward presence of central inflammatory involvement in both RA 
and allergy pathogenesis, we sought to confirm this hypothesis in study I and II by 
investigating microglia activation in the CNS of RA patients and allergic subjects using PET. 
We were not able to confirm this hypothesis as no difference in microglia activation was 
detected between either RA patients or allergic subjects and their controls. Furthermore, no 
relation was found between central microglia activation and peripheral inflammation or 
fatigue  in RA or allergy, autonomic dysfunction in RA patients or sleep measures in allergic 
subjects. However, it remains to be noted that low grade central inflammatory events may 
not be reflected by increased glial activation as measured by TSPO expression leaving the 
question of central inflammation in RA and Allergy and relations to CNS related symptoms 
to be conclusively answered in future investigations. In study I we provide further evidence 
of the close relation between ANS dysfunction and circulating levels of inflammatory 
mediators. In study II we provide evidence that allergen exposure is associated with 
increased levels of not only circulating IL-5 but also TNFα and that being allergic is 
associated with higher IL-5 levels even when not exposed to allergen. 
In study III we sought out to investigate central inflammation and relation to CNS related 
symptoms from a different angle in arthritis patients. This was done by exploring proteomic 
changes in CSF of arthritis patients treated with biologic blockade of TNFα since this 
treatment strategy is known to be able to ameliorate certain CNS related symptoms. We 
demonstrate for the first time that TNF-blockade exerts considerable effects on the 
proteome in CSF of arthritis patients and identify 35 CSF proteins decreased by treatment. 
Of these proteins, the majority show involvement in inflammatory processes, thus adding to 
the growing expanse of circumstantial evidence supporting central inflammatory 
involvement in arthritis. Furthermore, we identify fibrinogen gamma and complement factor 
B as a likely important players in central nervous inflammation, as well as contactin-1 and 
cell adhesion molecule 3 as potentially involved in pain sensitisation/regulation which 
should be investigated further. 
Since one of the CNS related features associated with RA is reduced vagal activity, VNS is 
tested as a feasible treatment strategy to restore parasympathetic, i.e. CAP, function 
although much remain to be understood about CAP mechanism of action. In study IV we 
therefore explore the extent of CAP mediated effects on the immune system and in study V 
investigate mechanistic involvement of PGE2 in the CAP. We here provide the first evidence 
that CAP mediated effects extend to NK cells. Additionally, we provide evidence that CAP 
effects are not limited to the spleen and that those effects may be organ specific. We also 
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demonstrate for the first time that a functional mPGES-1 and subsequent PGE2 production is 
essential for ChAT upregulation following engagement of β2AR as well as for inhibition of 
pro-inflammatory cytokine release following engagement of α7nAChR in splenocytes 
subjected to endotoxaemia. 
Although not confirmed in study I and II we provide further evidence of central 
inflammatory involvement in arthritis in study III, pinpointing several proteins likely 
involved in this central inflammatory response and CNS related symptoms. Using 
experimental murine models in study IV and V we extend our mechanistic insight into the 
anti-inflammatory properties of the CAP important to consider when applying VNS as an 
anti-inflammatory treatment strategy in human chronic inflammatory diseases. 
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6 FUTURE PERSPECTIVE 
A big step forward for a PhD student is a small step forward for the scientific community 
towards understanding neuroimmune involvement in chronic inflammatory diseases. Thus, 
even though this thesis has led to an advancement of our current understanding of neuro-
immune mechanisms it has also pin-pointed several questions in wanting of answers from 
future research projects.  
For example, so far only few studies have considered altered HRV in allergy patients hinting 
at withdrawal of sympathetic activity and increased vagal activity210,317. Could allergy 
patients then have an abnormally active CAP? Engagement of β2AR on immune cells is 
known to promote a Th2 environment156,157. Together with the fact that PGE2 also has the 
capacity to shift an immune response toward not only Th2 but also B cell IgE 
production143,152 and our report of a functional CAP depending on PGE2 (study V), could an 
overactive CAP thus provide an environment suitable for initiation/sustention of allergen 
reactive Th2 and B cells? Could a side effect of chronic VNS be increased predisposition to 
allergy? Could allergy itself be treated by sympathetic stimulation or inhibition of vagal or 
β2AR activity? How is PGE2 involved in allergy? Do allergy patients have altered PGE2 levels 
and in such a case would that relate to peripheral inflammation, central inflammation and 
symptoms?  
Furthermore, CAP effects were shown in study IV to be extended to NK cells and possibly 
Th1 cells, both important sources of IFNγ and both indicated in RA disease pathology. 
Together with our reports in study I of increased peripheral levels of IFNγ in RA patients 
and an overall inverse relation between IFNγ and vagal activity raise questions about the 
status of circulating Th1 and NK cells in RA patients and possible relations to autonomic as 
well as disease activity. Interestingly , in study III one of the proteins identified as down 
regulated in CSF of arthritis patients after TNF-blockade was NCAM-1, which is also 
known as CD56, the primary surface marker used to identify human NK cells 30. Is there an 
inflammatory driven influx of NK and other immune cells into arthritis CSF? Could such an 
influx explain generation of CNS related symptoms?  
Data sets and a number of parameters collected from study I, II and III are considerably 
large and the work of analysing all aspects of these data sets has only just begun. With HRV 
measurements recorded also from allergy patients and their controls in and out of pollen 
season, investigations are currently underway to address some of the questions raised 
regarding HRV involvement in allergy. Furthermore, potential associations between 
additional aspects of fatigue measurements and microglia activity in brain regions of interest 
in RA remain to be investigated. Study I and II additionally included flow cytometric 
analysis data of blood cells, which is currently investigated to address some of the questions 
regarding circulating immune cells and relations to disease symptoms and activity in RA and 
allergy. Furthermore, a project to investigating immune cell status in CSF in RA has been 
initiated. 
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Regarding the proteins identified as decreased in CSF of IFX treated arthritis patients 
(study III) only a minority has so far been thoroughly investigated and continued efforts 
with the rest of the identified proteins will surely reveal many more interesting candidates. 
And much more work remains to further investigate these in arthritis and inflammatory 
models to pinpoint their specific function and contribution to arthritis, inflammation and 
CNS related symptoms. 
Answering all of these questions and more inevitably raised along the way will go far 
towards understanding disease initiation and progression of disease pathology as well as 
indicating new and improved treatment strategies in chronic inflammatory conditions. 
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